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ABSTRACT

Medication non-adherence and non-persistence are pressing issues in healthcare today.
Their resultant health and economic ill-effects are well studied in numerous diseases. To help
improve medication adherence and persistence, their effective and efficient measurement is
essential. Thus, the purpose of this dissertation was to develop the Medication Non-Adherence
Scale (MNAS) and the Medication Non-Persistence Scale (MNPS).
The scales were administered to patrons of three independent community pharmacies in
the Southeastern United States. Their responses were anonymously linked to prescription fill
data. The MNAS was validated against the past 6 months of prescription fill data, while the
MNPS against the past 12 months. The MNAS was also tested against 3 months of prospective
data to study its ability to predict future non-adherence.
Confirmatory factor analyses offered evidence for internal consistency reliability, and
convergent and discriminant validity. The results indicated a 5 factor solution for the MNAS –
worries about side-effects, worries about addiction, worries about cost, lack of perceived need,
and unintentional non-adherence – and a single factor solution for the MNPS. Linear regression
analyses concluded that the scales demonstrated concurrent validity (MNAS: unstandardized
regression coefficient=-0.50 (p<0.001); MNPS: unstandardized regression coefficient=-3.97
(p=0.03)). Another linear regression analysis also offered evidence for the MNAS having
predictive validity (unstandardized regression coefficient=-0.62 (p<0.001)). ROC curve analysis
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suggested that a score of greater than 16 on the MNAS indicated non-adherence in the past 6
months, and a score of greater than 20 indicated non-adherence in the next 3 months. A score of
1 or higher on the MNPS indicated non-persistence in the past 12 months.
The MNAS was seen to perform better than the Medication Adherence Reasons Scale
(MAR-Scale: R2=0.016, standardized regression coefficient=-0.125; MNAS: R2=0.043,
standardized regression coefficient=-0.208) and the 1986 Morisky scale (R2=0.018, standardized
regression coefficient=-0.134) in estimating concurrent PDC, and better than the Adherence
Estimator (AE: R2=0.010, standardized regression coefficient=-0.099; MNAS: R2=0.083,
standardized regression coefficient=-0.288) in estimating future PDC. These estimates were also
statistically significantly different from each other.
Thus, the MNAS and MNPS help fill vital gaps in adherence and persistence
measurement, and may be used by healthcare practitioners and researchers to improve patient
health.
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LIST OF ABBREVIATIONS AND SYMBOLS

Abbreviation

Description

A14

Adherence 14

ACE

Angiotensin-converting enzyme

AE

Adherence Estimator®

ARB

Angiotensin-receptor blocker

ASK-20

Adherence Starts and Knowledge-20

AVE

Average variance extracted

BARS

Brief Adherence Rating Scale

BB

Beta-blockers

BBQ

Beliefs and Behaviour Questionnaire

BMQ

Brief Medication Questionnaire

CCB

Calcium channel blocker

CFA

Confirmatory factor analysis

CMS

Centers for Medicare & Medicaid Services

CR

Composite reliability

DUA

Data Use Agreement

DV

Dependent variable

GLM

General Linear Model

HIPAA

Health Insurance Portability and Accountability Act

IV

Independent variable

LM

Lagrange Multiplier

MAM

Medical Adherence Measure

MARS

Medication Adherence Rating Scale

MAR-Scale

Medication Adherence Reasons Scale

MEMS

Medication Event Monitoring System
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MID

Unique mailing identifier

MMAS

Morisky Medication Adherence Scale

MNAS

Medication Non-Adherence Scale

MNAS-I-Addiction

Intentional non-adherence due to worries about addiction
to the medication

MNAS-I-Cost

Intentional non-adherence due to worries about cost of
the medication

MNAS-I-Perceived need Intentional non-adherence due to lack of perceived need
of the medication
MNAS-I-Side-effects

Intentional non-adherence due to worries about sideeffects

MNAS-U

Unintentional non-adherence

MNPS

Medication Non-Persistence Scale

MPR

Medication possession ratio

MUAH

Maastricht Utrecht Adherence in Hypertension

NCQA

National Committee for Quality Assurance

NICE

National Institute of Health and Clinical Excellence

PDC

Proportion of days covered

PQA

Pharmacy Quality Alliance

PTID

Unique patient identifier

RAM

Reported Adherence to Medications

ROC

Receiver-operating characteristic

WLSMV

Weighted least squares with mean and variance
adjustment
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CHAPTER I:
INTRODUCTION

1

BACKGROUND

Importance of Studying Medication Adherence and Medication Persistence
It has been estimated that 30-60% of prescribed medicines are not taken as directed.1,2
Such behaviors usually involve medication non-adherence or medication non-persistence.2,3,*
Numerous studies have demonstrated the resultant ill-effects of these behaviors. For example, Ho
and colleagues identified the adverse effects of non-adherence to medications used to treat
diabetes mellitus on all-cause hospitalizations and all-cause mortality.4 Studies have also shown
that discontinuation of relevant medication therapy post myocardial infarction (i.e. aspirin, βblockers, and statins) can lead to a statistically significant increase in mortality.5 Sokol et al.
concluded that patients with diabetes mellitus, hypertension, hypercholesterolemia, or congestive
heart failure who were non-adherent to their medications had statistically significantly greater
hospitalizations. Such behavior was also observed to lead to higher overall health care costs.6
According to the 2011 Express Scripts Drug Trend Report, an excess of $317.4 billion may have
been spent due to medication non-adherence in that year.7 Due to these reasons, such behaviors
have been referred to as “the ‘other’ drug problem”.8 In order to counter this issue, effective and
efficient measurement of medication adherence and persistence is necessary.
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Measurement of Medication Adherence
Medication adherence has been operationalized in multiple ways. Some of the often used
methods are described below.
Direct patient observation. In this method, as the title suggests, patients are directly observed
while taking their medications. Such a technique is direct and objective.9,10,† This is often
considered the ideal method to measure medication adherence, but when used in the outpatient
setting or in large studies, its practicality has been questioned.9,11 Also, as pointed out by
Garfield et al.12, and Osterberg and Blaschke9, intentionally non-adherent patients may “hide
pills in the mouth and then discard them.” This may lead to a bias in classification of individuals
as adherent or non-adherent.
Drug level in biological fluids / biological assays and biomarkers. These methods detect the
presence of the drug, an associated metabolite, or the biomarker in a biological fluid. In the case
of biomarkers, markers are added to the biological fluids in order to detect the presence of the
drug or associated metabolites.11 The advantage of these methods is that they are direct and
objective techniques of estimating medication adherence9,10 But using these methods on a routine
basis is difficult. Also, as mentioned by Farmer11, these method do not measure patients’ actual
medication-taking behavior; despite having the required level of the drug or associated
metabolite in the biological fluids, the patient may not have consumed the medication as
directed. Thus, there is little evidence to suggest that the patient will follow medication-taking
directions in the future.11
Pill counts. This is one of the most commonly used methods to measure medication adherence in
clinical trials.13 It is also used in clinical practice.11 Pill counts are considered to be objective and
3

indirect measures of medication adherence9,10 This method involves counting the number of
dosage units (tablets, capsules, etc.) that are not consumed by a patient at the time of the
scheduled check. The percentage of compliance is then calculated by dividing the number of
dosage units consumed by the expected number of dosage units that should have been consumed
(taking the number of units prescribed and the days’ supply into consideration), and multiplied
by 100. Despite its relative simplicity, it has a severe disadvantage – patients may discard their
dosage units prior to the scheduled check to appear more adherent (e.g. pill dumping). Thus, pill
counts often overestimate adherence behavior.14–17
Prescription refill records and administrative claims data. The use of these data sources in
the measurement of medication adherence has increased drastically with the availability of drug
insurance claims data.11,18–22 Proportion of days covered (PDC) and medication possession ratio
(MPR) have been identified as the most appropriate measures of medication adherence using
administrative claims data.23–26 These methods are considered objective but indirect.9,10 The
formulae for measuring PDC and MPR have been given below.26–29
MPR =

Sum of the days supply for all fills of the drug in the study period
Number of days in the study period

PDC =

Number of days the patient is covered by the drug in the study period
Number of days in the study period

PDC offers a more conservative estimate.29 The calculation of PDC takes potential
overlaps and gaps in therapy into consideration. Although either of these methods is accepted in
pharmacoepidemiology, pharmacoeconomics, and health outcomes research, some limitations
exist. While using prescription records as a surrogate of medication-taking behavior, the
researcher must make a few assumptions – the data are complete, i.e. all the necessary variables
and records are present11, and a prescription fill indicates that the medication was consumed.9
4

But in reality, unless the data were obtained from a closed system (e.g., a nationalized health care
system) there may be individuals who have obtained a prescription fill from a source other than
the one available to the researcher (other pharmacy, other health care insurer, etc.), and a
prescription fill may not indicate that the medication was consumed.9 Being cognizant of these
assumptions and taking possible steps to prevent invalidation of obtained values is essential.
Electronic monitoring. Electronic monitoring of medication adherence is done by implementing
devices that have a microchip built into them. These are classified as objective, but indirect
methods.9,10 An example of such devices is the Medication Events Monitoring System (MEMS)
cap.14 This is a special prescription bottle cap that collects data every time it is opened. The
numbers reported by the MEMS cap can be accurate down to the second at which the cap was
opened. This device can help collect continuous, and relatively reliable data.11,14,30 The MEMS
caps have been used to measure medication adherence in numerous studies.14,31–36 Their
successful empirical performance has often resulted in them to being called the “gold standard”
measure of medication adherence.14,30,37 They, however, have some drawbacks. Firstly, they are
expensive and cumbersome; they require a visit to the location where the data are being collected
for downloading information. Secondly, and perhaps more importantly, they measure the times
when the bottles were opened and not when the medication was consumed. If a patient simply
opens and shuts the cap (unintentionally, or otherwise), a datum is recorded. This could
adversely affect medication adherence measurement.11,12,38
Self-reporting. Broadly, there are three types of patient self-reporting methods – patient diaries,
patient interviews, and questionnaires.11 In the case of patient diaries, patients are asked to
maintain a diary to record their daily medication-taking behavior. Patient interviews are
unstructured, potentially unstandardized and non-validated interviews conducted to obtain
5

medication adherence-related information from patients. On the other hand, questionnaires are
structured, standardized, and often formally tested for their psychometric properties. They are
used to obtain empirical data about medication adherence from patients.11 Self-reporting has
often been criticized for offering less reliable and valid estimates of medication adherence.15,19,39–
41

These methods cannot be classified as objective or direct.9,10 Despite this, the National

Collaborating Centre for Primary Care and the Royal College of General Practitioners (London,
UK), along with National Institute of Health and Clinical Excellence (NICE) commended these
measures as being the most appropriate for monitoring medication adherence in clinical
practice.12,42 The primary reason for this is their feasibility, practicality, and simplicity.9,11,43 In a
clinical setting, other, potentially more valid, reliable, and objective measures such as MEMS,
bioassays, biomarkers, prescription refill records, pill counts, etc. are often considered
impractical and expensive.12 Such a setting requires an instrument that is quick and easy to
administer, and gives immediate results. Only a self-reported questionnaire is capable of such a
task.12 Moreover, a recent review by Shi and colleagues concluded that self-reported measures
demonstrate moderate to high correlation with electronically monitored measures of medication
adherence, further strengthening the evidence of the capability for these measures.44 Thus, a selfreported scale is the preferred choice for a health care practice setting administrable measure of
medication non-adherence.

Need for a Better Medication Adherence Scale
Disease non-specificity. Currently, the 1986 Morisky scale is the most widely used self-reported
measure of medication adherence in the clinical setting.45 Although commonly used, data
supporting its use offer mixed results. Some studies have reported low internal consistency
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reliability, while others report acceptable levels.33,45–49 The primary reason for its popularity is its
ability to be used as a disease non-specific instrument.33,46,48–50 Although the scale was developed
in hypertensive patients, it has yielded similar results in other disease conditions.33,46,48,49 The
Morisky scale was updated in 2009 to improve upon its internal consistency.51 The Morisky
Medication Adherence Scale (MMAS) has twice the number of items (as compared to the 1986
version)‡, and to the best of our knowledge, has only been tested among hypertensive and
diabetic patients.51–55 In 1999, Horne et al. published the Reported Adherence to Medication
(RAM) scale.56 Although this scale too has been used in multiple disease conditions, it has not
been found to report beyond moderate psychometric properties.49,56,57 Another drawback of this
scale is that it uses different units of measurement for half of its items.56 This may lead to
difficulties in its interpretation; an important property in a practice setting.
Distinguishing between different reasons for medication non-adherence. In their recent
systematic review, Garfield et al. stated the need for a better disease non-specific measure of
medication adherence.12 In doing so, they outlined three desirable characteristics of such a scale
– pragmatic (inexpensive, short, non-intrusive, and flexible to the mode of administration),
having good psychometric properties (reliable, valid, sensitive, and specific), and having a sound
theoretical foundation (use of an appropriate theory).12 A theoretical foundation is essential. But
using an appropriate theory is even more important. Virtually every health behavior theory has
been tested in the context of medication adherence – social learning theory/social cognitive
theory, theory of reasoned action/theory of planned behavior, health belief model,
transtheoretical model, etc. – albeit offering inconsistent results.58–62 Garfield and colleagues
argue that the reason for such results is that these theories assume that the medication nonadherence behavior was intentional.12 They, along with many others in recent years, suggest that
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it is important to distinguish between intentional and unintentional non-adherence.43,50,57,63–69,§
Such a classification can help in distinguishing between the reasons for non-adherence.
Usually, the purpose of measuring medication adherence in a clinical setting is to
intervene and improve it. The underlying rationale for non-adherence is very different in the case
of intentional and unintentional non-adherers. Thus the intervention techniques needed to
improve medication adherence are different as well.12 In the case of intentional non-adherence,
intervention strategies may focus on the physician-patient relationship, implementation of
behavioral strategies (using e.g. health behavior models), etc.43,58,67,70 While in the case of
unintentional non-adherence, strategies such as pill-boxes, reminder phone calls, text messages,
emails, etc. would be more beneficial.12,68,** Studies have used existing scales to distinguish
between these two forms of non-adherence. Some studies have used the 1986 Morisky scale,
while others have used the RAM scale.45,50,56,69,††,‡‡ A recent study by Krousel-Wood and
colleagues recommends the used of the Morisky Medication Adherence Scale (MMAS) for this
purpose.55 However, as mentioned earlier, this scale has not been tested outside hypertensive and
diabetic patients.51–55 Thus, its applicability is limited.
Garfield et al. recommended the use of the model of accident causation proposed by
Reason§§ to help distinguish between intentional and unintentional medication nonadherence.12,63,64,71,72 Barber adapted Reason’s framework to the context of medication nonadherence.63,***,††† According to this model, unintentional non-adherence can be a result of a
‘slip’ or a ‘lapse’, where a slip is an outcome of lack of attention (e.g. taking the wrong dose,
taking the wrong pill, etc.), and lapse, a “failure of memory” (e.g. forgetting to take a dose,
forgetting that a dose has already been taken, etc.).63 Intentional non-adherence can be a result of
a ‘mistake’ or ‘violation’. Mistakes are correct actions that have gone awry. They are further
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separated into ‘rule-based mistakes’, and ‘knowledge-based mistakes’. Rule-based mistakes
occur when a patient either incorrectly applies a good rule, or correctly applies a bad rule to
tackle a particular scenario (e.g. stopping treatment with a non-addictive drug due to the fear of
the possibility of getting addicted to it). Knowledge-based mistakes occur when no pre-existing
rule applies to the situation at hand, and the patient must apply his/her knowledge (e.g. rather
than getting a prescription refill immediately after a prior fill runs out unexpectedly, the patient
decides against this being an emergency and delays this task).63 Violations, on the other hand, are
“deliberate deviations from safe practice” (e.g. choosing not to pick up a prescription as the
patient feels that the physician did not pay heed to his/her comments, not following the dosage
regimen directed by the physician and taking all medications together rather than at separate
times, etc.).63
Arguing against the use of this binary categorization of non-adherence, Unni and Farris
developed the Medication Adherence Reasons Scale (MAR-Scale).73,74 They suggest that the
intentional-unintentional classification limits the ability to identify specific reasons for nonadherence.74 In the recently modified version of their scale, they categorized the reasons for nonadherence as having four factors – practicality issues (e.g. not being able to open the container,
pharmacy being out of medicine, etc.), lack of necessity belief issues (e.g. perceived need for
medication, perceived effectiveness of medication, etc.), forgetfulness issues, and concern belief
issues (e.g. possible side-effects or long-term effects). This classification was developed based
on the Anderson’s Behavioral Model75, Leventhal et al.’s Common-Sense Model76,77, and the
data collected in their study73. The items in the MAR-Scale were based on the conclusions
reached by a systematic review conducted by Vik et al.10, and other studies pertaining to
medication non-adherence.78–82
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Estimation of health care quality. The Pharmacy Quality Alliance (PQA) considers medication
adherence as an essential component of medication-use quality.83 They recommend the use of
proportion of days covered (PDC) to measure medication adherence. Specifically, they
recommend calculation of medication adherence for seven therapeutic classes outlined by the
National Committee for Quality Assurance (NCQA) – beta-blockers (BBs), angiotensinconverting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), calcium channel
blockers (CCBs), biguanides, sulfonylureas, thiazolidinediones, and statins.84 PDCs are also used
by the Centers for Medicare & Medicaid Services (CMS). Their current guidelines use measures
of medication adherence to determine bonus payments to capitated medicare advantage plans.85
The problem with PDCs is that they can only be calculated on retrospective data.
Considering their importance, it is necessary to develop a scale that can provide a self-reported
estimate of the PDC. Such a scale may help health care practitioners assess the quality of care
being provided prior to the analysis of retrospective prescription fill data. Our literature review
did not identify any disease non-specific self-reported measures of medication non-adherence
that have been tested to estimate concurrent PDCs.
Thus, there is a need for a psychometrically-sound, self-reported measure of medication
non-adherence, which is disease non-specific, theory-based, capable of distinguishing between
the different reasons for non-adherence, and provides an estimate of the PDC measure.

Measurement of Medication Persistence and Need for a Self-Reported Instrument
Medication persistence is usually operationalized as the duration of time from initiation
to discontinuation of therapy, after accounting for therapeutically permissible gaps.3,23,28,84,86 This
requires the use of prescription claims, pharmacy refill, pill counts, or clinical trials data.3,23,87,88
10

According to our review of the literature, currently, there are no multi-item self-reported
measures of medication persistence in the scientific literature or health care practice that have
been validated and tested for their reliability. But due to numerous issues with stopping
pharmacotherapy without the consent of a health care provider, it is necessary to develop an
instrument that can help identify patients who have been non-persistent with their medications,
and the reasons behind such behavior.5,23 Thus, the development of such a self-reported measure
is pertinent.

Predicting Future Medication Adherence
Along with the assessment of concurrent medication adherence, estimating future nonadherence behavior is often of value to health care practitioners and researchers alike. Several
self-reported instruments have been developed to aid in the identification of patients who have a
higher propensity of being non-adherent to prescription medications.89–114 The authors identified
five measures that have been developed for, or validated in, multiple chronic diseases – the
Adherence 14 (A14) scale93, the Adherence Starts and Knowledge-20 (ASK-20) scale99, the
Medical Adherence Measure (MAM)106, the Beliefs and Behaviour Questionnaire (BBQ)111, and
the Adherence Estimator (AE)112–114. Out of these, only the AE has been tested for its predictive
validity using prospective pharmacy claims data.113 The AE is a 3-item instrument used to assess
“proximal beliefs related to intentional non-adherence.”113 These items assess the patients’
perceived importance of their prescription medication(s), worries about potential side/adverse
effects, and perceived financial burden. This instrument has presented good psychometric
properties and has been shown to successfully predict future medication non-adherence.112–114
However, due to its focus on intentional medication non-adherence, the prediction of potential

11

unintentional medication non-adherence is left unaddressed. Thus, development of a scale that
can predict a wider scope of future non-adherence behaviors is necessary.

12

SPECIFIC AIMS

As mentioned in the prior section, medication non-adherence and non-persistence are
important issues in health care.1,2,4–7 Despite this, there are numerous gaps in the measurement of
these constructs.12 This dissertation sets forth the following specific aims to bridge such gaps in
the literature:
Paper 1: To develop two self-reported measures – the Medication Non-Adherence Scale
(MNAS) and the Medication Non-Persistence Scale (MNPS)
o The MNAS will be a health care practice setting administrable, disease nonspecific measure of medication non-adherence with the ability to distinguish
between the different reasons for non-adherence, and provide a self-reported
estimate of the proportion of days covered (PDC) measure23,26–29
o The MNPS will be a health care practice setting administrable, disease nonspecific measure of medication non-persistence.
Paper 2: To test the ability of the MNAS in predicting objectively measured future
medication non-adherence (i.e., using PDCs)
Paper 3: To compare the abilities of the MNAS and other relevant scales in predicting
objectively measured medication non-adherence; specifically:
o

To compare the ability of the MNAS, the 1986 Morisky scale, and the MARScale in predicting objectively measured concurrent medication non-adherence
(i.e., using PDC)
13

o To compare the ability of the MNAS and the Adherence Estimator®xi in
predicting objectively measured future medication non-adherence (i.e., using
PDC)27,112–115

14

SIGNIFICANCE

Medication Non-Adherence Scale (MNAS)
This dissertation is concerned with the development of two self-reported measures, the
first of which is the Medication Non-adherence Scale (MNAS). This scale was designed to offer
the following properties:


Health care practice setting administrable



Disease non-specific



Ability to distinguish between the different reasons for non-adherence



Provide a self-reported estimate of the proportion of days covered (PDC) measure



Predict future medication non-adherence
Although, as discussed in earlier sections, many of the current self-reported scales

possess some of the properties mentioned above, our literature review did not reveal any measure
that bore all of these properties. Thus such a scale may offer multiple benefits to health care
practitioners and researchers.

Medication Non-Persistence Scale (MNPS)
This dissertation is also concerned with the development of the Medication NonPersistence Scale (MNPS). As addressed earlier, this will be the first multi-item self-reported
measure of medication persistence in contemporary scientific literature. Development of the
15

MNPS may offer health care practitioner and researchers a much needed insight into the reasons
behind medication non-persistence.
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The literature refers to four terms in the area of medication-taking behaviors – adherence, compliance, persistence,
and concordance.1–3 One is often confused for the other. Concordance, a term more prominent in the United
Kingdom, is used to denote a “therapeutic alliance” between the health care practitioner and the patient. 1,116 It
embodies the epitome of contemporary patient-centered care. Although often classified as a medication-taking
behavior, Horne and colleagues state that it paints a more normative picture. 2 Persistence refers to taking ones
medications long-term, continually.88 It is also defined as the amount of time that a patient follows the prescribed
treatment regimen.3 If a patient follows the prescribed therapy (after accounting for therapeutically permissible
gaps), he/she is said to be persistent. Adherence and compliance are often used interchangeably. There are however,
subtle differences. Compliance assumes that the patient is merely, and passively, following the health care
practitioner’s “orders”, while adherence considers the patient in a more active role (takes medication, follows diet,
brings about lifestyle changes, etc.).1,2,117 In today’s world of patient-centered care, the term ‘adherence’ is generally
preferred by health care practitioners as ‘compliance’ may suggest oppression or order-following.1,9 Thus in this
dissertation, the term ‘adherence’ will be used to depict this type of medication-taking behavior.
†
Two types of classifications of methods for measuring medication adherence are most commonly found in the
literature – direct versus indirect9,11, and objective versus subjective10. Direct methods purport to measure actual
medication adherence (e.g. by direct patient observation, or biological assays and biomarkers), and are said provide
“proof” of adherence11, while indirect measures use surrogates such as prescriptions filled, opening of prescription
bottle cap, pills remaining, etc.9 Self-reported measures are considered to be subjective measures, while all other
methods discussed here are considered to be objective. This distinction has been made on the premise that responses
to self-reported measures may be affected by issues like social desirability bias118, making them more ‘subjective’.10
‡
As emphasized by Garfield and colleagues in their recent review, when the purpose of the instrument is
administration in a clinical setting, the length of the instrument is important. 12 Thus, shorter the instrument, lesser
the time spent by the health care practitioner on adherence assessment.
§
A point to note here is that the use of the term ‘adherence’ (or ‘non-adherence’) implies that the patient plays a
more active role in medication-taking behavior. It is this assumption of an active role that enables the possibility of
intentional medication non-adherence. If a patient were assumed to play a passive role in medication-taking (i.e.
along the lines of ‘compliance’), the distinction between the intentionality of such behavior would have been
virtually impossible 67,68.
**
Contrary to this, Unni and Farris119 concluded that in the case of Medicare enrollees, “concern beliefs” in
medications were a significant predictor of unintentional non-adherence. Their operationalization of unintentional
non-adherence was based on the 1986 Morisky scale. They recommend that this finding demands further study.
††
For the 1986 Morisky scale: two items are used to represent intentional non-adherence (“When you feel better do
you sometimes stop taking your medicine?”, “Sometimes if you feel worse when you take the medicine, do you stop
taking it?”), and two for unintentional non-adherence (“Do you ever forget to take your medicine?”, “Are you
careless at times about taking your medicine?”) 50.
‡‡
For the RAM: the item used to measure intentional non-adherence is: “Some people […] say that they miss out a
dose of their medication or adjust it to suit their own needs. How often do you do this?” While the item used to
measure unintentional non-adherence is: “Some people forget to take their medicine. How often does this happen to
you?”
§§
This framework has also been called the ‘accident causation framework’ and the ‘human error theory’. 12,63,64
***
Barber named his adaptation of the model, ‘medical error theory’.
†††
‘Non-adherence’ has been termed ‘non-compliance’ in Barber’s 2002 adaptation of the model of accident
causation, but based on Lehane and McCarthy’s arguments, and to be consistent with the rest of this research
proposal, we will continue referring to this medication-taking behavior as non-adherence.63,67,68
xi
Adherence Estimator is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,
Whitehouse Station, NJ, USA. US and non-US Patents Pending. Copyright © 2008 Merck Sharp and Dohme Corp.,
a subsidiary of Merck & Co., Inc. All rights reserved.
*

39

CHAPTER II:
PAPER 1
DEVELOPMENT OF THE MEDICATION NON-ADHERENCE SCALE (MNAS) AND THE
MEDICATION NON-PERSISTENCE SCALE (MNPS)

In preparation for Medical Care
Format adapted for dissertation

40

ABSTRACT

Background
Although there are numerous self-reported measures of medication non-adherence in the
scientific literature, no single measure has demonstrated evidence of having good psychometric
properties, being disease non-specific, distinguishing between the different reasons for nonadherence, and offering an estimate of the proportion of days covered (PDC) measure. Also,
there is no multi-item self-reported measure of medication non-persistence in the scientific
literature or health care practice.
Objectives
To develop two self-reported measures – the Medication Non-Adherence Scale (MNAS) and the
Medication Non-Persistence Scale (MNPS)
Research Design
A cross-sectional survey containing the MNAS and the MNPS was administered to patrons of
three independent community pharmacies. The patients’ survey responses were linked with their
prescription fill data to study the internal consistency reliability, and convergent, discriminant
and concurrent validity of the scales being developed.

41

Subjects
A total of 685 patrons of three independent community pharmacies located in the Southeastern
region of the US were included in the sample for analysis involving the MNAS, and 675 for
analysis involving the MNPS.
Measures
The MNAS assessed the extent and reasons for non-adherence, and the MNPS assessed the
reasons for non-persistence. PDC was used as the criterion measure of validating the MNAS,
while ‘days to discontinuation’ performed this function in the case of the MNPS.
Results
The MNAS presented with a five factor solution – Intentional non-adherence due to worries
about side-effects, intentional non-adherence due to worries about addiction to the medication,
intentional non-adherence due to worries about cost of the medication, intentional non-adherence
due to lack of perceived need of the medication, and unintentional non-adherence. The MNPS
yielded a single factor solution. Both scales demonstrated strong evidence of internal consistency
reliability (all Cronbach’s α values and composite reliabilities were greater than 0.7), and
convergent (all standardized factor loadings were greater than 0.5 and significant, and no
evidence of cross-loadings was observed), discriminant (all chi-square difference values were
above the critical value, and all average variance extracted values were at acceptable levels) and
concurrent validity (relationships between the MNAS and PDC (unstandardized regression
coefficient = -0.50 (p < 0.01)), and MNPS and days to discontinuation (unstandardized
regression coefficient = -3.97 (p = 0.03)) were statistically significant and in the expected
direction). Based on a ROC curve analysis of the MNAS, individuals who score more than ‘16’
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on the scale were considered non-adherent. Individuals who score more than ‘0’ on the MNPS
were considered non-persistent.
Conclusions
The Medication Non-Adherence Scale (MNAS) and the Medication Non-Persistence Scale
(MNPS) demonstrated good psychometric properties. They have been designed to help fill
crucial gaps in relevant literature and health care practice. If used in a health care practice
setting, these scales may help identify reasons behind such behavior, and aid in the development
of tailored interventions to improve patient health.
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INTRODUCTION

Medication non-adherence occurs when a patient misses, skips, delays, or takes more/less
of the dose of the prescribed medication regimen.1–5 Medication non-persistence refers to
stopping or discontinuation of the treatment regimen.4,6 Such behaviors are important issues in
health care.1,2,7–10 Many studies conducted in chronic conditions such as diabetes mellitus,
hypertension, hypercholesterolemia, and congestive heart failure have demonstrated the
detrimental effects of medication non-adherence and non-persistence on hospitalizations,
mortality, and resultant overall health care costs.8–10 Due to these reasons, effective and efficient
measurement of medication non-adherence and medication non-persistence is necessary.
There are numerous methods of measuring medication non-adherence in the scientific
literature and healthcare practice. Broadly, these may be divided into ‘objective methods’ and
‘subjective methods’.11 Objective methods include biological assays, pill counts, use of the
electronic devices (e.g. Medication Events Monitoring System (MEMS)), pharmacy records and
prescriptions claims, etc., while subjective methods include patient interviews, patient diaries
and self-reported questionnaires. Despite the abundance of methods, no measure is universally
agreed upon as a ‘gold standard'.5,11–18 As each of these instruments measure the construct
differently, recent papers suggest that rather than anointing a measure as a gold standard, the
choice of measurement should depend on the demands of the situation.14 In a health care practice
setting, which is the focus of the current study, self-reported questionnaires may be the only
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pertinent tool to measure medication non-adherence. This argument is supported by the National
Collaborating Centre for Primary Care and the Royal College of General Practitioners (London,
UK), along with National Institute of Health and Clinical Excellence (NICE), and corroborated
by Garfield and colleagues.14,19
There are many self-reported instruments available for measuring medication nonadherence – 1986 Morisky scale20, Medication Adherence Reasons Scale (MAR-Scale)21,
Medication Adherence Rating Scale (MARS)22, Brief Medication Questionnaire (BMQ)23,
Maastricht Utrecht Adherence in Hypertension (MUAH)24, Brief Adherence Rating Scale
(BARS)25, Morisky Medication Adherence Scale26, etc. Currently, the most widely used selfreported measure in a clinical setting is the 1986 Morisky scale.20 The primary reason for its
popularity is its short length and its ability to be used as a disease non-specific instrument.27–31.
Despite these advantages, it has often presented issues with psychometric properties.20,27,28,30–32
The Morisky scale was updated in 2009 to improve upon its reliability, but this version has twice
the number of items (as compared to the 1986 version), and has only been tested among
hypertensive and diabetic patients.26,33–36
Another shortcoming of many current instruments is that they often do not explicitly
distinguish between the different reasons for medication non-adherence.14,37 Some scientific
papers propose distinguishing the reasons for non-adherence based on intent, into intentional and
unintentional non-adherence.14,38,39 Intentional medication non-adherence occurs when a patient
makes a conscious decision to not comply with the medication regimen (e.g. stopping medication
due to side- or adverse-effects, perceived lack of need, unaffordability, etc.). Unintentional
medication non-adherence occurs when a patient simply forgets to take his/her medication(s). In
their recent paper on the development of the Medication Adherence Reasons Scale (MAR45

Scale), Unni and Farris stressed on the importance of further distinguishing between the different
reasons for intentional non-adherence. They observed that non-adherence can occur due to four
issues – practicality issues (e.g. not being able to open the container, pharmacy being out of
medicine, etc.), lack of necessity belief issues (e.g. perceived need for medication, perceived
effectiveness of medication, etc.), concern belief issues (e.g. possible side-effects or long-term
effects), and forgetfulness issues. Irrespective of the depth of classification implemented, the
necessity of distinguishing between the different reasons for medication non-adherence is
unhindered because the interventions needed to counter each type are quite different.14,37 For
example, reminder phone calls, SMSs, emails, etc. may work while intervening upon
unintentional medication non-adherence or forgetfulness issues, while counseling may be
necessary for dealing with intentional medication non-adherence or any of the other three issues
mentioned in the MAR-Scale.
Medication persistence is usually measured using prescription claims data, pharmacy
refill records, pill counts, or clinical trials data.4,6,40,41 It is most often operationalized as the
amount of time from initiation to discontinuation of the treatment regimen, or as a binary
variable depicting whether the regimen was followed over the observation period or not.4,6,40,42–44
Studies have indicated that behaviors such as stopping pharmacotherapy without the health care
provider’s consent may result in adverse health and/or economic issues.9,10,40 Thus identification
of patients who may have been non-persistent with their medications is important. Based on the
recommendations by the National Collaborating Centre for Primary Care and the Royal College
of General Practitioners (London, UK), and National Institute of Health and Clinical Excellence
(NICE), this may be achieved by the use of self-reported measures.19 But currently, health care
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research and practice lacks multi-item self-reported measures of medication non-persistence.
Such measures can also aid in the identification of reasons for non-persistence.
In order to address these gaps in current scientific literature, this paper proposes the
development of the Medication Non-Adherence Scale (MNAS) and the Medication NonPersistence Scale (MNPS). As discussed above, the MNPS is the first multi-item self-reported
measure of medication non-persistence. Thus, its development is important to health care
research and practice. But there are numerous self-reported measures of medication nonadherence in the scientific literature. The MNAS has been designed to offer five beneficial
properties. First, it is designed to be disease non-specific. This will enable implementation of the
MNAS in a variety of therapeutic areas. Second, the MNAS is grounded in theory. Conventional
health behavior theories such as the social learning theory/social cognitive theory, theory of
reasoned action/theory of planned behavior, health behavior model, transtheoretical model, etc.
offer explanations for intentional medication non-adherence.45–49 The model of accident
causation promises to explain the intentional and unintentional aspects of this medication-taking
behavior, and has been recommended as a conceptual framework for aiding in the
operationalization of this distinction.14,38,39,50,51 According to this model, unintentional
medication non-adherence can be defined as a ‘slip’ (an outcome of lack of attention) or a ‘lapse’
(an outcome of forgetfulness), while intentional medication non-adherence can be defined as a
‘mistake’ (intentional implementation of an inappropriate action in a given scenario) or
‘violation’ (a deliberate implementation of an normatively unsafe action).38 The MNAS is based
on this model, and the suggestions offered by Unni and Farris21,37 in their development of the
Medication Adherence Reasons Scale (MAR-Scale). This ability to distinguish between the
different reasons for medication non-adherence is the third advantage offered by the MNAS.
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Fourth, it is developed using proportion of days covered (PDC) as the criterion measure. This
objective measure is recommended for the measurement of medication adherence for use in the
assessment of pharmacy quality by the Pharmacy Quality Alliance (PQA) and the Centers for
Medicare and Medicaid Services.52,53 Thus, the MNAS will offer self-reported estimates of the
patients’ PDCs to health care providers who choose to use it. Finally, the ultimate goal of this
scale development exercise is to offer practitioners a relatively short, simple, and readily
interpretable instrument to help assess medication non-adherence in a practice setting. Although
other scales offer many of the properties discussed above, to the best of our knowledge, no scale
offers all five. The MNAS has the potential of helping health care practitioners and researchers
improve their assessment of medication non-adherence.
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METHODOLOGY

Description of the Proposed Instruments
The Medication Non-Adherence Scale (MNAS) has been designed as a disease nonspecific instrument with the ability to distinguish between the different reasons for medication
non-adherence. The instrument is based on Barber’s adaptation of the model of accident
causation proposed by Reason38,39,50,51, and the insight offered by Unni and Farris21,37 in the
development of the Medication Adherence Reasons Scale (MAR-Scale). The items were
developed based on the 1986 Morisky scale20, the Medication Adherence Scale (MAS)54, the
Morisky Medication Adherence Scale26, the Medication Adherence Rating Scale (MARS)22, the
Reported Adherence to Medication (RAM) scale55, and the guidance offered by Barber38,39,
Garfield et al.14, and Unni and Farris21,37. All items were scored from ‘1’ through ‘5’on a five
point Likert-scale with options ‘Never’, ‘Rarely’, ‘Sometimes’, ‘Often’, and ‘Always’. The final
scale items can be viewed in the appendix.
Unlike the MNAS, which is theory-based, development of the MNPS was an exploratory
endeavor. The MNPS items can be viewed in the appendix. The items were worded such that a
binary (yes or no) response is obtained. Each pro-non-persistence response was coded as ‘1’,
while each pro-persistence response will be coded as ‘0’. These scores were summed to form one
patient specific score for medication non-persistence. A summated score of ‘0’ (zero)

49

represented perfect medication persistence, while anything higher indicated some form of nonpersistence.

Pretests
Prior to conducting the study, the MNAS and the MNPS underwent two rounds of
qualitative pretest evaluations (Pretest 1 and 2), and one round of quantitative pretest evaluation
(Pretest 3). Pretest 1 was conducted among eight faculty members at a university in the
Southeastern region of the United States with experience in self-reported scale development. The
purpose of this pretest was “subjective validation” (i.e. face and content validity) of the scales.56
It was conducted by distributing the then current versions of the MNAS and MNPS to the sample
frame via email, and receiving feedback by the same medium. This feedback was evaluated, and
appropriate suggestions were incorporated into the wording of the items. Pretest 2 was conducted
among six staff members at the same university, who were users of prescription medications for
chronic conditions. Its purpose was to assess sources of response error in the proposed
instruments by conducting six cognitive interviews.57–60 Based on the arguments presented by
Beatty and Willis, a combination of ‘think-aloud’ and ‘probing’ techniques were used to help
improve the scales.57 Patients were recruited via email. Their responses were recorded using a
digital voice recorder. They were offered a $10 gift card to an online store in exchange for their
participation. The voice recordings were transcribed, and important points were marked for
consideration. The MNAS was modified by adding two items pertaining to unintentional nonadherence, and one pertaining to intentional non-adherence. The MNPS was left unaltered.
Pretest 3 was conducted to empirically assess internal consistency reliability (Cronbach’s
alpha and composite reliability), and convergent and discriminant validity of the MNAS and
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MNPS, and their potential to invoke a socially desirable response.61–65 To achieve these aims, a
cross-sectional, observational study was conducted by administering the scales as an internetbased survey to a convenience sample of full-time students, faculty, and staff at a university in
the Southeastern region of the United States, who take at least one prescription medication
indicated for a chronic condition. In order to help increase sample size, the patients were entered
into a drawing to win one of ten $25 gift cards to an online store. This method yielded 214 usable
responses. The instrument administered contained six sections – screener, the MNAS items, the
MNPS items, socially desirable response bias assessment questions65, demographic
characteristics, and patient comments. Patients were screened based on the number of
medications for chronic conditions prescribed; only patients that consumed at least one such
medication were included in the study. Data collected were analyzed in SAS 9.3 (SAS Institute
Inc., Cary, NC) and Mplus 7.2 (Muthén & Muthén, Los Angeles, CA, USA). For calculating
internal consistency reliability, Cronbach’s alphas were calculated using the ‘CORR’ procedure
in SAS with the ‘ALPHA’ option*, and composite reliability was calculated using the method
described by Fornell and Larcker.61,62 Further, convergent and discriminant validity of the
measures was tested using the procedures outlined by Anderson and Gerbing, and Kline.63,64
Details about these procedures can be found in the analysis section of the study below. These
analyses resulted in a two factor solution for the MNAS – intentional non-adherence and
unintentional non-adherence – and a one factor solution for the MNPS. Based on these results
and the statements mentioned in the comments section of the survey, two items were added to
the MNAS – “I missed a dose of my medication because I did not get it refilled before I ran out”
and “I missed a dose of my medication because I forgot to take it with me”. Also, the need-based
items in the MNAS were reworded to exclude the “at that time” portion of the statements. The
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MNPS was modified by adding an item – “I stopped taking my medication because the
medication did not work”. Potential for socially desirable response bias was tested using the
method described by Steenkamp, de Jong, and Baumgartner.65 No statistical evidence of such
bias was observed.

Study
Following changes to the MNAS and MNPS based on the results of the pretests, the
scales were administered to a sample of patients currently consuming medications for
hypertension, diabetes, and dyslipidemia.†
Study objectives and study design. This study had the following objectives:


To calculate internal consistency reliability of the MNAS and MNPS (using Cronbach’s
alpha, and composite reliability as instructed by Fornell and Larcker)61,62



To study convergent and discriminant validity of the MNAS and MNPS using the methods
outlined by Anderson and Gerbing, Kline, and Fornell and Larcker62–64



To study the concurrent validity of the MNAS and MNPS using measures calculated using
prescription fill data as their respective objective measures (an adaptation of the NCQA
PDC measure‡ and time to discontinuation, respectively)4,40



To calculate sensitivity and specificity of the MNAS and MNPS by classifying their scores
into meaningful categories using receiver-operating characteristic (ROC) curves66,67
A retrospective observational study was conducted to meet these objectives. Data for the

MNAS and MNPS were collected from patrons of three independent community pharmacies in
the Southeastern United States. Retrospective prescription fill data for these patrons were
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obtained from the pharmacies under consideration, and the self-reported data were linked with it
to meet the aforementioned objectives.
Sample design and data collection. The target population of the study was prescription
medication users who have been directed by their health care provider to consume at least one
prescription medication indicated for a chronic condition. After finalizing Data Use Agreements
(DUAs) with three independent community pharmacies in the Southeastern region of the United
States, prescription fill data were obtained for a 12-month period prior to the date of data
request§. These data were used to identify the sample frame. In these data, patients were only
referenced using a unique patient identifier (PTID). Patients, 18 years and older, were selected
based on whether they filled at least one prescription for a medication in one of the seven
therapeutic categories of interest specified by the National Committee for Quality Assurance
(NCQA)44, starting at least 6-months prior to the end of the data. These therapeutic categories
included beta-blockers (BBs), angiotensin-converting enzyme (ACE) inhibitors or angiotensinreceptor blockers (ARBs), calcium channel blockers (CCBs), biguanides, sulfonylureas,
thiazolidinediones, and statins.44 Only PTIDs that had prescription fills for at least one of the
seven categories, and starting at least 6 months before the end of the data, with the last fill ending
at least 90 days after the first started, were included in the sample frame. This resulted in a
sample frame with 4,554 patients. The PTIDs in these data were then linked to patient names and
addresses by an independent data manager. The involvement of the independent data manager
ensured that the researchers did not have access to any patient identifiers in accordance with the
Health Insurance Portability and Accountability Act (HIPAA).68
Survey instrument packets were then created for each patient in the sample frame. These
packets included a cover letter from the patronized pharmacy informing the patients about the
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study and the survey instrument (containing a screener for whether they used the pharmacy we
obtained their data from for most of their medications, the MNAS, MNPS, and demographic
questions) printed on a business reply mailer, and were enclosed in an envelope with the
appropriate name and address printed on a label on top. Each survey instrument contained a
unique mailing identifier (MID) that was patient specific, and linked to the PTID. A matching
MID was also printed on the address label to ensure that the survey instrument reached the
correct patient. The MID was linked to the PTID by the researchers, and the PTID was linked to
the patients’ names and addresses by the independent data manager; neither had access to the
other’s crosswalk files. This method of using a second-level ID (rather than using the PTID for
mailing) was implemented to further ensure that patients’ identities were not exposed. The
packets were then mailed via the United States Postal Service. Recipients were expected to
complete the instrument and mail it back using the business reply mailer.
Data management. Data collected using the survey instrument were manually entered into a
Microsoft Excel file. These data were then cleaned to eliminate patients who did not responded
to items on the MNAS and MNPS (or provided invalid responses) and did not use the pharmacy
we obtained their data from for most of their medications. The dataset was then converted into a
SAS dataset and merged with the prescription fill data using the MID and PTID. This resulted in
a single patient-fill level file. This file was further aggregated into a patient-therapeutic category
level file. Each patient was assigned their own observation period based on the date of survey
return postmark. For calculating the adaptation of the NCQA PDC measure, the observation
period ranged from 7 months prior to the date of survey return postmark to 1 month after, while
the measurement period ranged from the start of the first prescription fill 6 months prior to the
date of survey return postmark to the end of the last prescription fill on or before that date (i.e.
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date of survey return postmark). A 6-month measurement period was chosen based on the recall
period for the MNAS. A 30-day period prior to the start of the measurement period was observed
(pre-measurement period) to account for potential prescription fill overlaps from that period, and
a 30-day period was observed after the end of the last fill in the measurement period (postmeasurement period) to distinguish between potential discontinuation (i.e. absence of a
prescription fill/refill for the therapeutic category under consideration in the post-measurement
period) and potential non-adherence (i.e. presence of a prescription fill/refill for the therapeutic
category under consideration in the post-measurement period). If potential non-adherence was
observed, the measurement period was altered to end on the date of survey return postmark (even
if the “last prescription fill” ended before this date). Data within the measurement period were
used to calculate PDCs using the following formula42,69–71:
PDC =

Number of days the patient is covered by the drug in the measurement period
Number of days in the measurement period

A days to discontinuation score was also calculated for each therapeutic category consumed. For
this calculation, the observation period ranged from 13 months prior to the date of survey return
postmark to 1 month after. The measurement period, in this case, ranged from the start of the
first prescription fill 12 months prior to the date of survey return postmark to the end of the last
prescription fill on or before that date (i.e. date of survey return postmark). A 12-month
measurement period was chosen in concordance with the MNPS recall period. The days to
discontinuation score was calculated by adding the days until a gap in medication therapy of 30
days or more was experienced by the patient.42–44 The therapeutic category-specific PDCs and
days to discontinuation scores thus obtained were then averaged to calculate patient-specific
mean PDCs and days to discontinuation scores.43 Further, the patient-specific mean days to
discontinuation score was standardized by dividing by number of days in the patient’s
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measurement period and multiplying by 100. This was done to make the measure comparable
across patients, as is in the case of PDCs. Thus the standardized patient-specific mean days to
discontinuation score represented the number of days to discontinuation in a 100-day
measurement period. Based on the NCQA guidelines for calculating PDCs, a minimum drug
coverage of 90 days for MNAS validation, and 150 days for MNPS validation, was deemed
appropriate.44
Data analysis. All analyses were conducted in SAS 9.4 and Mplus 7.3. Two confirmatory factor
analyses (CFAs) were conducted. One CFA was conducted for MNAS in SAS 9.4 with
maximum likelihood estimation, and the other for MNPS in Mplus 7.3 with robust weighted least
square estimation (WLSMV – weighted least squares with mean and variance adjustment).**
Final factor structures were established for the two scales using the results of additional
exploratory factor analyses conducted on the Pretest 3 data as a guideline. The first aim of this
study was to calculate internal consistency reliability. This was done using two methods. First,
Cronbach’s alphas were calculated for the sub-scales of MNAS, and MNPS using the CORR
procedure in SAS 9.4 with the ALPHA option. Second, composite reliabilities (CR) were
calculated for these scales using the method described by Fornell and Larcker.62 This involves
using the values obtained in the confirmatory factor analyses described above in the formula
below:
CR =

Sum of standardized factor loadings squared
(Sum of standardized factor loadings squared + Sum of standardized error terms)

The second aim of this study was to test the convergent and discriminant validity of the
MNAS and the MNPS. The results of the confirmatory factor analyses conducted for objective 1
were used to achieve this objective as well. To check for convergent validity, standardized factor
loadings were observed to identify items with values below 0.5. Statistically nonsignificant
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standardized factor loadings were then identified.63 Further, modification indices (Lagrange
Multiplier (LM) statistics) were inspected for evidence of potential cross-loadings (i.e., large
values of LM statistics).64
Discriminant validity for the MNAS was assessed using the approach suggested by
Anderson and Gerbing.63 In this technique, the completely unconstrained model (in this case, the
MNAS model on which the CFA was originally run) is referred to as the base model. The chisquare estimate for this model is noted. Then, covariance between each pair of factors is
iteratively fixed at one, one at a time. At each iteration, the model is run, and the chi-square
estimate is noted. If this difference between each such estimate and that of the base model is
found to be greater than 3.84 (at α = 0.05), we can say that there is evidence of discriminant
validity between the corresponding pair of factors. In addition to these calculations, average
variance extracted (AVE) was also calculated for the MNAS sub-scales, and the MNPS.62 The
formula for calculating AVE has been given below:
AVE =

Sum of squared standardized factor loadings
(Sum of squared standardized factor loadings + Sum of standardized error terms)

If an AVE value is observed to be greater than or equal to 0.5, or if it is lesser than 0.5 but is
greater than its squared correlation with the other sub-scales/scale, we can say that there is
evidence to suggest discriminant validity.62
The scores on items under each sub-scale were then summed to denote the score on that
sub-scale. In order to study the concurrent validity of the MNAS, two multiple linear regressions
were conducted. The first model contained the summated forms of the MNAS sub-scales as
independent variables (i.e. each sub-scale as a separate IV), important demographic variables as
covariates††, and the patient-specific mean PDC measure as the dependent variable. The second
model replaced the summated sub-scale scores in the prior model with a summated overall
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MNAS score (i.e. only one IV). The SAS 9.4 GLM procedure was used for these analyses (using
a significance level of 0.05).
Using a procedure similar to that outlined above, concurrently validity of the MNPS was
studied against the standardized patient-specific days to discontinuation measure of persistence.
A multiple linear regression was conducted using the summated MNPS score as the independent
variable, important demographic variables as covariates††, and the standardized patient-specific
days to discontinuation score as the dependent variable. This was done using PROC GLM in
SAS 9.4 (using a significance level of 0.05).
The last objective of this study was to classify the scores on the MNAS and the MNPS
into meaningful categories. This was done to allow calculation of sensitivity and specificity of
the scales, and more importantly, enable better interpretability in a health care practice setting.
To do this, two receiver-operating characteristic (ROC) curves were plot, one for the MNAS, and
another for the MNPS. This was done using the LOGISTIC procedure in SAS 9.4 with the
PLOTS = ROC option. First, the patient-specific mean PDC and the patient-specific days to
discontinuation (i.e. non-persistence) variables were converted into their categorical forms. In the
case of PDC a 95% adherence criteria was used; individuals with a PDC of 95% or more were
classified as ‘adherent’, while those with a PDC of less than 95% as ‘non-adherent’.‡‡ For the
standardized days to discontinuation measure, individuals who had not discontinued any of their
medications in the measurement period (i.e. when value on this measure was 100) were classified
as ‘persistent’, while all others as ‘non-persistent’. The ROC curve for MNAS were plot using
the overall average MNAS score and the categorical patient-specific PDC variable. Similarly, the
summated score on the MNPS, and the dichotomous standardized patient-specific days to
discontinuation score were used to calculate the persistence ROC curve. These curves, and the
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dataset generated from the LOGISTIC procedure (using the OUTROC option) were used to
determine optimum cut-off points for the proposed scales.
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RESULTS

Sample Description
After 40 days in the field, 831 completed responses were obtained, while 611 packets
were returned by the USPS due to address issues. Thus, a response rate of 21.08% was observed
(831 ÷ (4,554-611)). Following this, patients who either provided invalid responses to the MNAS
or MNPS items, or did not use one of the three pharmacies under consideration for most of their
medications for chronic conditions were eliminated. This resulted in the elimination of 124
patients. Furthermore, as mentioned in the prior section, different minimum drug coverage
criteria were applied for MNAS (90 days) and MNPS (180 days) validation. Due to this, two
separate patient-level files were created – the MNAS analysis file containing 685 patients, and
the MNPS analysis file containing 675.
Table 1 provides information about the MNAS and MNPS sample characteristics.
Considering the fact that patients were required to consume at least one medication for a chronic
condition, and were administered a paper instrument (rather than online), the sample primarily
comprised of middle-aged to old individuals. About 63% of the MNAS sample and about 60% of
the MNPS sample was greater than 60 years of age. Considering that the number of medications
prescribed usually increase with age, such an age distribution was deemed appropriate for the
purposes of this study. The sample was also primarily white (87.3% for MNAS, 87.7% for
MNPS), female (56.5% for MNAS, 56.9% for MNPS), and married (64.8% for MNAS, 65.3%
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for MNPS). About 26% reported to having at least a college degree in either sample. Most
patients (65.8% in both samples) were prescribed 3 to 8 medications for chronic conditions, with
at least one of them being for diabetes, hypertension or dyslipidemia. Around 60% of either
sample were either insured by Medicare, private insurance, or both, and most reported their
health status as being ‘good’ (41.9% for MNAS, 39.9% for MNPS).

Confirmatory Factor Analysis, Internal Consistency Reliability, and Convergent and
Discriminant Validity
Results of the confirmatory factor analysis for the MNAS can be viewed in Table 2.§§
The analysis yielded a five factor solution – Intentional non-adherence due to worries about sideeffects (MNAS-I-Side-effects – 4 items), intentional non-adherence due to worries about
addiction to the medication (MNAS-I-Addiction – 2 items), intentional non-adherence due to
worries about cost of the medication (MNAS-I-Cost – 2 items), intentional non-adherence due to
lack of perceived need of the medication (MNAS-I-Perceived need – 4 items), and unintentional
non-adherence (MNAS-U – 4 items). Confirmatory factor analysis results for the MNPS can be
viewed in Table 3. This analysis yielded a single factor solution. The MNAS and MNPS items
can be viewed in the appendix. Cronbach’s α and composite reliability values for the MNAS
sub-scales and MNPS can be viewed in Table 4. These values were greater than the
recommended minimum of 0.7 on both measures.61,62,72 Based on these results, we can say that
we have sufficient evidence of internal consistency reliability for all sub-scales of MNAS and the
MNPS.
Next, standardized factor loadings obtained in the CFA were observed to identify
statistical nonsignificance and value below 0.5 (see Table 2 and 3). No such instance was
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observed. After accounting for correlated errors in the MNAS model, all Lagrange Multiplier
statistics were within limits, and no evidence of potential cross-loadings was observed. These
findings indicated sufficient evidence of convergent validity.63,64
The method suggested by Anderson and Gerbing63 and average variance extracted
(AVE)62 were used to assess discriminant validity in the MNAS, while only the latter was used
for the MNPS. Using the prior approach for the MNAS, all chi-square differences observed were
greater than 3.84 (critical value at α = 0.05). The AVE value for all summated MNAS sub-scales
scores, except unintentional non-adherence, was greater than 0.5. In the case of MNAS-U, AVE
was observed to be 0.49. However, as this value was higher than the squared correlations of
MNAS-U with the other sub-scales, all the MNAS sub-scales were concluded to demonstrate
discriminant validity. AVE for the MNPS was computed to be 0.62, thus offering evidence for
discriminant validity. The AVE values, correlation coefficients, and squared correlation
coefficients can be viewed in Table 4.

Concurrent Validity
The MNAS sub-scale item scores were first summed, and then subjected to concurrent
criterion validation using the patient-specific mean PDC. Based on the results of a set of
univariable analyses conducted by regressing the patient-specific mean PDC on each measured
demographic variable, the variable ‘age’ (measured in years) was included in the analysis as a
covariate. First, the patient-specific mean PDC was regressed on the five MNAS sub-scale
scores. This analysis indicated that the factor concerned with intentional non-adherence due to
worries about medication costs (MNAS-I-Costs) was the only sub-scale that was statistically
significantly associated with the patient-specific mean PDC (unstandardized regression
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coefficient = -1.94 (p < 0.01)). Also, the relationship between patient-specific mean PDC and the
factor concerned with intentional non-adherence due to a perceived lack of need of medication
(MNAS-I-Perceived need) was marginally significant (unstandardized regression coefficient = 0.71 (p = 0.08)).*** A second linear regression model was run to assess the relationship between
the summated overall MNAS score and patient-specific mean PDC. Result of this analysis
indicated that there was a statistically significant relationship between the overall MNAS score
and the patient-specific mean PDC (unstandardized regression coefficient = -0.50 (p < 0.01)).
These results can be viewed in Table 5. Thus, based on this result, we can say that there is
evidence to suggest that the MNAS has concurrent validity with the patient-specific mean PDC.
To assess concurrent validity of the MNPS, the scores on the items were summed to
calculate one patient-specific MNPS score. Similar to the concurrently validation of the MNAS,
a model building approach was used and the variable ‘age’ was included in the criterion
validation analysis with the standardized patient-specific mean days to discontinuation score.
The relationship between the MNPS score and the objective measure was not found to be
statistically significant (unstandardized regression coefficient = -0.84 (p = 0.21)). As the
development of the MNPS was an exploratory exercise, scoring on the MNPS was modified to
enable better prediction of the objective measure; the summated MNPS variable was modified to
a dichotomous variable with a value of ‘1’ for patients with a score of ‘1’ or more on the original
MNPS (i.e. those who answered ‘Yes’ on at least one of the 9 items), and a value of ‘0’ for
patients with a score of ‘0’ (i.e. those who did not answer ‘Yes’ on any item). After this
modification, the MNPS was seen to demonstrate a statistically significant relationship with the
standardized patient-specific mean days to discontinuation score (unstandardized regression
coefficient = -3.97 (p = 0.03)). These results can be viewed in Table 6. Based on this result, we
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can say that there is evidence to suggest that the MNPS has concurrent validity with the
standardized patient-specific mean days to discontinuation score.

ROC Curve Analysis, Sensitivity, Specificity and Meaningful Categorization of Scale
Scores
The ROC curve for MNAS presented a c statistic of 0.63. The dataset generated with the
OUTROC option provided a range of predicted probabilities, sensitivity, and 1-specificity
values. Using Youden’s J73 as a guideline, a cut-off point of 16.60 was obtained.††† At this point,
the scale had a sensitivity of 0.74 and specificity of 0.45. To improve implementation of the
MNAS in estimating PDC at a health care practice setting, because a score beyond 16 on the
MNAS indicated that the patient selected a response other than ‘Never’ on at least one item, a
cut-off point of 16 was deemed appropriate (a score beyond 16 indicates non-adherence), and
thus finalized. At this point, the sensitivity was 0.81 and specificity was 0.30.
For the MNPS, the c statistic was observed to be 0.53 and the relationship between the
original form of the scale and dichotomous standardized patient-specific days to discontinuation
score was not statistically significant. Thus no further attempt was made to arrive at a cut-off
point using this method. Rather, the dichotomous MNPS variable created in the concurrent
validation process was considered to be the best representation of the scale for use in a health
care practice setting, i.e. a score beyond 0 on the MNPS indicated non-persistence (as measured
using the standardized patient-specific days to discontinuation score). However, this cut-off point
yielded a sensitivity of only 0.24. The specificity value at this point was 0.82.
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DISCUSSION

Numerous papers have demonstrated the ill-effects of non-adherence.8–10 Yet based on
our literature review, no self-reported adherence measure in health care practice has presented
with good psychometric properties, is designed to be disease non-specific, and can help
distinguish between the different reasons for non-adherence. This paper presents evidence for the
Medication Non-Adherence Scale (MNAS) bearing those properties. Also, the ability of the
MNAS in offering a self-reported estimate of the proportion of days covered (PDC) measure40 is
presented here.
There is also evidence to suggest that non-persistence results in a similar, if not worse,
health and economic impact as non-adherence.9,10 But the construct lacks a method of
measurement that can offer health care practitioners an immediate estimate of their patients’
relevant behaviors, and reasons for the same. This paper develops and presents evidence for one
such measure – the Medication Non-Persistence Scale (MNPS).

Interpretation of Results and Recommendations for Use in a Practice Setting
A CFA of the MNAS yielded a five factor solution with four factors (worries about sideeffects, worries about addiction to the medication, worries about cost of the medication, and lack
of perceived need of the medication) concerned with intentional non-adherence, and one with
unintentional non-adherence. The scale demonstrated good internal consistency reliability and
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validity (convergent, discriminant, and concurrent). The concurrent validity analysis indicated
that on average for every one unit increase in the overall MNAS score (higher score indicates a
higher level of medication non-adherence), the adapted 6-month PDC measure dropped by 0.5
percentage points. Also, the ROC curve analysis indicated that a score of greater than 16 on the
MNPS indicated a PDC of less than 95%. Thus if a patient presents with such a score on the
MNAS, the sub-scales must be assess to identify reason(s) for non-adherence. This assessment
can enable implementation of an appropriate medication adherence intervention strategy.
Results of the CFA conducted on the MNPS items indicated a single factor structure.
This scale demonstrated good internal consistency reliability and validity (convergent,
discriminant, and concurrent). Based on the analysis conducted during validation, a score of
greater than ‘0’ (zero) was deemed to indicate non-persistence, although this cut-off point
presented with a low sensitivity value (0.24). Furthermore, individuals who indicated nonpersistence on the MNPS were seen to stop medication consumption on average about four days
before those who did not, in a 100-day period; i.e. on average about 15 days earlier in a one year
period. If a patient presents with a score higher than ‘0’ on the MNPS, their responses should be
observed to identify the reason(s) for non-persistence, and an appropriate intervention strategy
should be implemented.

Limitations of the Scales and Directions for the Future
Although this paper demonstrates strong evidence for reliability, validity, and
applicability of the MNAS and MNPS, a few issues must be acknowledged before using these
scales for research or in health care practice. The pretests and the study were conducted in three
independent community pharmacies in the Southeastern region of the US, thus the authors
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cannot make any claim about generalizability beyond this geographic area. Future studies need to
test these scales in different geographic and socio-demographic samples to improve their external
validity.
The MNAS and MNPS presented good statistical predictability of their objective
counterparts, but the amount of variation explained in their respective criterion variables was
observed to be quite low – 5.87% for MNAS and 1.32% for MNPS. Users of these scales must
be cognizant of this shortcoming. The effect such an r2 is seen in the poor specificity value of the
MNAS (0.45). Such numbers potentially indicate an incomplete estimation of the objective
measure. Although a thorough attempt was made by employing multiple rounds of qualitative
and quantitative pretesting, future research should try and ensure that all aspects of the PDC
construct are estimated by including additional factors for other reasons for non-adherence and
non-persistence. One aspect of non-adherence that could be considered by future researchers is
‘over-dosing’. The authors attempted to include items purporting to measure over-dosing in the
MNAS, but they were removed due to model fit and cross-loading issues. An alternate
explanation for this occurrence is the presence of socially desirable response bias. Although no
statistical evidence was found for this bias in the pretests, it may have affected prediction in the
study.‡‡‡ This hypothesis requires confirmation.
The work presented here does not study the comparative effectiveness of contemporary
adherence scales in predicting PDC. Thus no claims can be made about the comparative
performance of the MNAS. Future studies should assess the ability of other contemporary
adherence scales like the 1986 Morisky scale20, Medication Adherence Reasons Scale21, etc. in
predicting PDC, and compare results obtained using the MNAS.
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Ideally, to develop better adherence interventions in a health care practice setting, having
an estimate of the propensity for non-adherence in the future is more beneficial than an estimate
of how a patient has behaved in the past. The Adherence Estimator® (AE)74–76 is an example of a
scale that has been developed for this purpose. The MNAS has not been tested for this ability.
Future studies should assess the comparative predictive ability of the MNAS and the AE.

Conclusion
This paper outlined the development of two self-reported instruments that can be used to
assess medication adherence and medication persistence in health care practice and research. The
Medication Non-Adherence Scale (MNAS) was shown to distinguish between different reasons
for non-adherence, and estimate concurrent and future medication non-adherence. It was tested
in patients consuming medications indicated for diabetes, hypertension, and/or dyslipidemia, in a
disease non-specific context. As indicated by a review of the literature, the Medication NonPersistence Scale (MNPS) is the first multi-item self-reported measure of medication persistence.
It was also tested in a similar disease non-specific context. Both scales were developed to enable
relatively easy interpretation in a clinical setting, and allow health care practitioners to
understand the reasons driving their patients’ medication taking behavior.
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Table 1
Description of MNAS and MNPS sample demographic characteristics
Demographic Characteristics

Age

Gender

86
Race

Education

Marital Status

MNAS

MNPS

#

%

#

%

<= 45

43

6.3%

42

6.2%

46 – 60

201

29.3%

200

29.6%

61 – 70

196

28.6%

194

28.7%

71 – 80

164

23.9%

161

23.9%

> 80

81

11.8%

78

11.6%

Male

228

33.3%

226

33.5%

Female

387

56.5%

384

56.9%

Missing

70

10.2%

65

9.6%

White

598

87.3%

592

87.7%

Other races

84

12.3%

81

12.0%

Missing

3

0.4%

2

0.3%

Up to high school graduate

277

40.4%

275

40.7%

Some college (no degree), trade or technical school, or associate degree

224

32.7%

222

32.9%

Bachelors, professional, or graduate degree

178

26.0%

174

25.8%

Missing

6

0.9%

4

0.6%

Married

444

64.8%

441

65.3%

Currently not married

240

35.0%

234

34.7%

1

0.1%

0

0.0%

Missing

Income

No. of Medications

87
Health Insurance

Health Status

Under $20,000

167

24.4%

164

24.3%

$20,000 to $39,999.99

166

24.2%

166

24.6%

$40,000 to $59,999.99

95

13.9%

94

13.9%

$60,000 to $79,999.99

64

9.3%

63

9.3%

$80,000 or more

145

21.2%

143

21.2%

Missing

48

7.0%

45

6.7%

1–2

83

12.1%

83

12.3%

3–4

170

24.8%

166

24.6%

5–6

166

24.2%

164

24.3%

7–8

115

16.8%

114

16.9%

9 – 10

56

8.2%

55

8.1%

> 10

72

10.5%

71

10.5%

Missing

23

3.4%

22

3.3%

Medicare

402

58.7%

393

58.2%

Medicaid

74

10.8%

73

10.8%

Private

435

63.5%

430

63.7%

Uninsured

39

5.7%

39

5.8%

Tricare

9

1.3%

8

1.2%

Don’t know

7

1.0%

7

1.0%

Missing

4

0.6%

3

0.4%

Excellent

20

3.1%

20

3.0%

Very Good

171

26.3%

169

25.0%

Good

272

41.9%

269

39.9%

Fair

180

27.7%

177

26.2%

Poor

4

0.6%

39

5.8%

Missing

2

0.3%

1

0.1%

88
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Table 2
Confirmatory factor analysis results for the Medication Non-Adherence Scale
Constructs and Itemsa

Standardized
Loadingb

MNAS – Intentional – Side-effects
I skipped a dose of my medication because I was worried about its side effects.

0.72

I skipped a dose of my medication because I was having side effects.

0.83

I took a smaller amount of my medication because I was worried about its side effects.

0.86

I took a smaller amount of my medication because I was having side effects.

0.79

MNAS – Intentional – Addiction

90

I skipped a dose of my medication because I was worried about getting addicted to it.

0.94

I took a smaller amount of my medication because I was worried about getting addicted to it.

0.89

MNAS – Intentional – Cost
I skipped a dose of my medication because I was worried about costs.

0.91

I took a smaller amount of my medication because I was worried about costs.

0.81

MNAS – Intentional – Perceived need
I skipped a dose of my medication because I was feeling better.

0.77

I skipped a dose of my medication because I did not need it.

0.70

I took a smaller amount of my medication because I was feeling better.

0.80

I took a smaller amount of my medication because I did not need it.

0.72

Constructs and Itemsa

Standardized
Loadingb

MNAS – Unintentional
I forgot to take a dose of my medication.

0.64

I missed a dose of my medication by mistake.

0.61

I missed a dose of my medication because I did not get it refilled before I ran out.

0.78

I missed a dose of my medication because I forgot to take it with me.

0.77

Overall Fit:
χ2 (and df)

91

CFI
RMSEA (90% CI)
a
b

The model accounted for high error correlations (Lagrange Multiplier statistics).
All standardized factor loadings were statistically significant at α = 0.001.

273.47 (df = 87)
0.98
0.06 (0.05, 0.06)
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Table 3
Confirmatory factor analysis results for the Medication Non-Persistence Scale
Constructs and Items

Standardized
Loadingd

93

I stopped taking my medication because I was worried about its side effects.

0.96

I stopped taking my medication because I was having side effects.

0.90

I stopped taking my medication because I was feeling better.

0.90

I stopped taking my medication because I was worried about getting addicted to it.

0.74

I stopped taking my medication because I did not need it anymore.

0.90

I stopped taking my medication because I did not want to take it.

0.76

I stopped taking my medication because it was inconvenient.

0.59

I stopped taking my medication because I was worried about costs.

0.58

I stopped taking my medication because the medication did not work.

0.68

Overall Fit:
χ2 (and df)
CFI
RMSEA (90% CI)
d

All standardized factor loadings were statistically significant at α = 0.001.

95.75 (df = 27)
0.96
0.06 (0.05, 0.07)
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Table 4
Sub-scale means, standard deviations, Cronbach’s α, correlations, composite reliability, and average variance extracted
Mean

Std.

Cronbach’s

Dev.

α

X1

X2

X3

X4

X5

X6

X1 MNAS-I-Side Effects

1.17

0.42

0.87

0.88/0.64

0.26

0.12

0.16

0.08

0.22

X2 MNAS-I-Addiction

1.11

0.40

0.91

0.51

0.91/0.84

0.12

0.21

0.08

0.19

X3 MNAS-I-Cost

1.25

0.60

0.85

0.35

0.34

0.85/0.74

0.12

0.20

0.12

X4 MNAS-I-Perceived Need

1.17

0.41

0.83

0.4

0.46

0.34

0.84/0.56

0.16

0.31

X5 MNAS-U

1.67

0.60

0.82

0.29

0.28

0.45

0.4

0.79/0.49

0.11

X6 MNPS

0.43

1.10

0.75

0.47

0.44

0.35

0.56

0.33

0.94/0.62

95

Note: Composite Reliabilities (CR) and Average Variance Extracted (AVE) are shown in bold on the Diagonal (CR/AVE). Correlations
are shown on the lower matrix while squared correlations are shown on the upper matrix.
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Table 5
Concurrent validation of the Medication Non-Adherence Scale
Dependent variable: Patients-specific mean PDC
Parameter

Estimatec

Std. Error

p-value

Model with MNAS sub-scale scores as independent variables (R2 = 0.0587)
Intercept

90.94

4.10

<0.01

MNAS-I-Side-effects

-0.16

0.40

0.69

MNAS-I-Addiction

0.85

0.86

0.32

MNAS-I-Cost

-1.94

0.54

< 0.01

MNAS-I-Need

-0.71

0.40

0.08

MNAS-U

-0.34

0.27

0.17

97

Model with overall MNAS score as independent variable (R2 = 0.0453)
Intercept

91.17

4.11

< 0.01

MNAS

-0.50

0.10

< 0.01

c

The estimates have been adjusted for ‘age’.
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Table 6
Concurrent validation of the Medication Non-Persistence Scale
Dependent variable: Standardized patient-specific mean days to discontinuation
Parameter

Estimatee

Std. Error

p-value

Model with original MNPS score (R2 = 0.0089)
Intercept

85.32

3.95

<0.01

MNPS

-0.84

0.67

0.21

Model with dichotomous MNPS score (R2 = 0.0132)
Intercept

86.23

3.96

<0.01

MNPS-Dichotomous

-3.97

1.86

0.03

(non-persistent vs. persistent)
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e

The estimates have been adjusted for ‘age’.

APPENDIX G

100

Medication Non-Adherence Scale (MNAS)
Over the past SIX MONTHS, how often have you done the following things without being advised to do so by your doctor?
Please respond to all of the following statements by selecting Never, Rarely, Sometimes, Often, or Always.
Never Rarely Sometimes Often Always
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I forgot to take a dose of my medication.











I skipped a dose of my medication because I was worried about its side effects.











I skipped a dose of my medication because I was having side effects.











I skipped a dose of my medication because I was feeling better.











I skipped a dose of my medication because I was worried about getting addicted to it.











I skipped a dose of my medication because I did not need it.











I skipped a dose of my medication because I was worried about costs.











I took a smaller amount of my medication because I was worried about its side effects.











I took a smaller amount of my medication because I was having side effects.











I took a smaller amount of my medication because I was feeling better.











I took a smaller amount of my medication because I was worried about getting addicted to it.











I took a smaller amount of my medication because I did not need it.











I took a smaller amount of my medication because I was worried about costs.











I missed a dose of my medication by mistake.











I missed a dose of my medication because I did not get it refilled before I ran out.











I missed a dose of my medication because I forgot to take it with me.
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Medication Non-Persistence Scale (MNPS)
Sometimes, people stop taking their medication. Have you done the following things in the past ONE YEAR without being advised
to do so by your doctor? Please circle your responses.
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I stopped taking my medication because I was worried about its side effects.

Yes

No

I stopped taking my medication because I was having side effects.

Yes

No

I stopped taking my medication because I was feeling better.

Yes

No

I stopped taking my medication because I was worried about getting addicted to it.

Yes

No

I stopped taking my medication because I did not need it anymore.

Yes

No

I stopped taking my medication because I did not want to take it.

Yes

No

I stopped taking my medication because it was inconvenient.

Yes

No

I stopped taking my medication because I was worried about costs.

Yes

No

I stopped taking my medication because the medication did not work.

Yes

No

*

As the MNPS items are dichotomous, the Kuder-Richardson 20 reliability measure will be equivalent to the
coefficient alpha.
†
The National Committee for Quality Assurance (NCQA) recommends the calculation of proportion of days
covered (PDC) for medications indicated for these three conditions. This measure is an essential component of the
measurement of health care quality, and is used by CMS and some other payers to enhance reimbursement to
providers.53 As an adaptation of the NCQA PDC measure will be used as the criterion measure to validate the
MNAS, the authors believe that limiting the study sample to these three conditions is justified.
‡
The difference between the NCQA PDC measure and the adaptation used in this study was the length of the
observation period – 12 months and 6 months, respectively. Due to this difference in observation period, the
minimum drug coverage period used was also shorter – 150 days for the NCQA measure and 90 days of the
adaptation.
§
A month was assumed to be a 30 day period for this study.
**
Due to the dichotomous nature of the MNPS items, a maximum likelihood estimation model was deemed
inappropriate.
††
Univariable linear regressions were conducted using each measured demographic variable as an independent
variable and the patient-specific mean PDC (or the standardized patient-specific days to discontinuation measure) as
the dependent variable. Variables that demonstrated statistically significant results were included in model as
‘important demographic variables’.
‡‡
A 95% criteria was chosen rather than the conventional 80% criteria 40,52,77 to enable better correspondence with
the wording and scoring of MNAS items.
§§
After looking at item distributions by using PROC UNIVARIATE in SAS 9.4, it was observed that most MNAS
items had a skewed distribution. Thus, two methods were implemented to confirm the results of maximum
likelihood estimation. First, the items were log transformed and estimated using maximum likelihood. Second,
Mplus 7.3 was used to conduct a CFA with robust weighted least squares (WLSMV – weighted least squares with
mean and variance adjustment).78–80 Both methods yielded identical factor structures. Thus to enable calculation of a
summated score by assuming that the items are linear, the model estimated using maximum likelihood was finalized.
***
Most MNAS items and the patient-specific PDC measure had a skewed distribution. Thus, two methods were
used to confirm the results of this regression. First, the patient-specific PDC measure was log transformed, and the
model was re-run. Second, the model was re-run using PROC GENMOD with a log link and a Gamma distribution.
Both methods yielded qualitatively identical results. The original ordinary least squares model was thus finalized to
enable ease of interpretation of results.
†††
This cut-off point was not decided based on the best Youden’s J (which would also have offered a cut-off point
of 17), but by assessing the top five J values and deciding in the favor of better sensitivity, rather than specificity.
This decision was made because when estimating non-adherence, false positives (getting identified as non-adherent
when actually adherent) are not as severe a problem as false negatives (getting identified as adherent when actually
non-adherent).
‡‡‡
The socially desirable response bias assessment questions were not included in the study as many Pretest 3
patients complained about the vague nature of those questions in the comments section. Upon finding no statistical
evidence of such a bias in Pretest 3, the authors decided not to include those questions in the study to avoid any
negative impact on the assessment of the non-adherence and non-persistence.
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CHAPTER III:
PAPER 2
PREDICTIVE VALIDATION OF THE MEDICATION NON-ADHERENCE SCALE (MNAS)

In preparation for Journal of the American Pharmacists Association
Format adapted for dissertation
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ABSTRACT

Objective
To assess the ability of the Medication Non-Adherence Scale (MNAS) in predicting future
medication non-adherence.
Design
Prospective observational study
Setting
Three independent community pharmacies in the Southeastern United States.
Participants
Five hundred and seventy-nine patients, 18 years of age and older, who were prescribed at least
one medication indicated for diabetes, hypertension, or dyslipidemia, and used one of the three
pharmacies approached for most of their medications.
Main outcome measure
A 3-month adaptation of the National Committee for Quality Assurance (NCQA) proportion of
days covered (PDC) measure.
Results
Three MNAS sub-scales – intentional non-adherence due to worries about medication cost
(unstandardized regression coefficient = -1.17 (p = 0.02)), intentional non-adherence due to lack
106

of perceived need of the medication (unstandardized regression coefficient = -0.75 (p < 0.05)),
and unintentional non-adherence (unstandardized regression coefficient = -0.65 (p = 0.01)) –
were observed to be statistically significantly associated with future medication non-adherence.
The overall summated version of the MNAS was also observed to estimate future PDC
(unstandardized regression coefficient = -0.62 (p < 0.005)). Results of the ROC curve analysis
demonstrated that a score beyond 20 on the MNAS may indicate incidence of medication nonadherence in the next three months.
Conclusion
This study demonstrated the ability of the MNAS in predicting medication non-adherence in the
next three months after administration.
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INTRODUCTION

Medication non-adherence is an important issue in health care.1–6 Numerous studies have
demonstrated its adverse effects on health care utilization in diseases such as myocardial
infarction, diabetes mellitus, hypertension, hypercholesterolemia, and congestive heart failure.2–
4,6

Studies have also concluded that such behavior can lead to an increase in the cost of health

care.2,6 Recent estimates indicate that an additional $317.4 billion may be attributable to nonadherence.2 Moreover, a report by Horne et al. concluded that 30 to 60% of medications are not
consumed as prescribed.5 Due to the expanse of this issue, numerous methods have been devised
to measure the construct – direct patient observation, drug level in biological fluids / biological
assays and biomarkers, pill counts, prescription refill records and administrative claims data,
electronic monitoring, and self-report.7–15
Some researchers propose that among the methods listed above, electronic monitoring
using MEMS should be considered a ‘gold standard’ measure.15–17 But recent papers suggest
that rather than anointing a gold standard, the choice of measure should depend on the
measurement setting.10 Due to their feasibility and practicality, self-reported measures appear to
be the only pertinent tool to measure medication non-adherence in a clinical practice setting,
which is the focus on the current paper. In accordance with this claim, the National Collaborating
Centre for Primary Care and the Royal College of General Practitioners (London, UK), and the
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National Institute of Health and Clinical Excellence (NICE) recommended the use of self-reports
in this setting.18
There are numerous self-reported measures of medication adherence in use in health care
research and practice today – 1986 Morisky scale19, Medication Adherence Rating Scale
(MARS)20, Brief Medication Questionnaire (BMQ)21, Brief Adherence Rating Scale (BARS)22,
Morisky Medication Adherence Scale23, Medication Adherence Reasons Scale (MARS)24, etc.
These measures have been developed to assess concurrent or past medication adherence
behavior. But oftentimes, prediction of future medication non-adherence behavior is equally
important. If estimated effectively, this may enable the implementation of interventions prior to
the potential occurrence of non-adherence, and may prevent its aforementioned negative impact.
Researchers have developed several instruments to help health care practitioners identify
patients with a higher propensity of being non-adherent.25–50 For such an instrument to be usable
in a wide range of practice settings, it must be disease non-specific. A review of the literature
revealed five scales that have been developed for, or validated in, multiple chronic conditions –
the Adherence 14 (A14) scale29, the Adherence Starts and Knowledge-20 (ASK-20) scale35, the
Medical Adherence Measure (MAM)42, the Beliefs and Behaviour Questionnaire (BBQ)47, and
the Adherence Estimator® (AE)48–50. The primary requirement of an instrument purporting to
assess patients’ future medication non-adherence, is an acceptable level of predictive validity.
Out of the five measures listed, the Adherence Estimator® (AE) is the only instrument that has
been tested for its predictive validity using pharmacy claims data.48–50 The instrument has
presented good psychometric properties and has yielded favorable results related to predictive
validity. It is a 3-item instrument, and these items measure patients’ perceived importance of
prescription medications, worries about potential side/adverse effects of the medications
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consumed, and perceived financial burden. Thus, the AE assesses the patients’ proximal beliefs
about intentional non-adherence.49
Many researchers in recent years have stressed on the importance of distinguishing
between different reasons for non-adherence.10,24,51 These are broadly divided into intentional
and unintentional medication non-adherence.10,52–61 This distinction is important because the
rationale for non-adherence is different in the case of its two forms. Thus, the methods needed to
intervene and improve future adherence are different as well. Strategies to counter intentional
non-adherence should focus on improving the patient-physician relationship, implementing
techniques derived from health behavior models, etc., while reminder phone calls/text
messages/emails, pills-boxes, etc. are more effective in the case of unintentional nonadherence.10,52,59,60,62,63 Moreover, Unni and Farris found evidence for further segregation of
intentional non-adherence into practicality issues, issues pertaining to a lack of perceived
necessity, and concern belief issues.51 Despite the AE’s commendable psychometric performance
and simplicity, the lack of an unintentional medication non-adherence component and some
aspects of the intentional non-adherence component, limits its applicability in a practice setting.
Thus, there is a need for a scale that can predict a larger spectrum of reasons for future
medication non-adherence to aid in the implementation of appropriate strategies to improve
patients’ medication-taking behavior.
The Medication Non-Adherence Scale (MNAS) promises to offer these properties.64 It
has been designed as a clinical practice setting administrable and disease non-specific measure of
medication non-adherence. The scale has been demonstrated to distinguish between five reasons
for non-adherence – worries about side effects, worries about addiction to the medication,
worries about cost of the medication, lack of perceived need of the medication, and unintentional
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non-adherence. It has been concurrently validated against an adaptation of the National
Committee for Quality Assurance (NCQA) proportion of days covered (PDC) measure65, among
patients prescribed medications indicated in diabetes, hypertension, and dyslipidemia. The
MNAS is based on Barber’s adaptation of Reason’s model of accident causation55,56,66,67, and the
suggestions offered by Medication Adherence Reasons Scale (MAR-Scale) developed by Unni
and Farris24,51. The items on the scales can be viewed in the appendix.
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METHODOLOGY

Study Objectives and Study Design
A prospective observational study was conducted to test the ability of the Medication
Non-Adherence Scale (MNAS) in predicting future medication non-adherence. Specifically, this
study had two objectives:


To assess the predictive validity of the MNAS using an adaptation of the NCQA PDC
measure as an objective measure of future medication non-adherence.14,65,68



To calculate sensitivity and specificity of the MNAS in predicting future medication nonadherence using receiver-operating characteristic (ROC) curves.69,70
Prescription fill data were obtained from three independent community pharmacy in the

Southeastern region of the US. Patrons of these pharmacies, who were prescribed at least one
medication indicated for diabetes, hypertension, or dyslipidemia were administered a survey
containing the MNAS. The survey data were linked to the prescription fill data, and used to meet
the aforementioned objectives.

Sample Design and Data Collection
Three independent community pharmacies in the Southeastern region of the United States
were approached to participate in the study. Upon approval of Data Use Agreements (DUAs), the
pharmacies were asked to provide prescription fill data for the past 7 months. These data were
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used to identify the sample frame. Patients, identified only by a unique encrypted patient
identifier (PTID), were selected based on whether they are 18 years of age or older, and filled at
least one prescription for medications indicated for diabetes, hypertension, or dyslipidemia.
Specifically, medications that fall under one of the seven therapeutic categories of interest
specified by the National Committee for Quality Assurance (NCQA) were considered. These
include beta-blockers (BBs), angiotensin-converting enzyme (ACE) inhibitors or angiotensinreceptor blockers (ARBs), calcium channel blockers (CCBs), biguanides, sulfonylureas,
thiazolidinediones, and statins.65 Survey instrument packets, containing a cover letter from the
pharmacy patronized and the survey instrument (with the MNAS and demographic questions),
were created for each patient in the sample frame. An independent data manager linked the
PTIDs to the patients’ names and addresses, and printed address labels to be posted on the survey
instrument packets. This was done to ensure that the researchers did not have access to the
patients’ identities. These packets were mailed to the patients, and they were expected to mail
back the completed instrument via the business reply mailer enclosed.* Four months after the
date of receipt of the last usable survey, the pharmacies were asked to provide an amendment to
the participants’ prescription fill data.†

Data Management
The survey data were linked to the prospective prescription fill data using PTID and an
encrypted mailing ID (MID)‡ as linking variables. The resultant patient-fill level file was then
aggregated to a patient-therapeutic category level file. This file was used to calculate the
proportion of days covered (PDC) measure for each therapeutic category of interest specified by
the National Committee for Quality Assurance (NCQA)65, using a 3-month prospective
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prescription data measurement period. A 3-month period was used to improve the feasibility of
the study. This 3-month period was patient specific, depending on, and starting from, the date of
survey return postmark. The fourth month of prospective data were used to distinguish between
potential non-adherence (i.e. if a prescription for a drug in the same therapeutic category is filled
or refilled in this fourth month) and non-persistence (i.e. if such a fill or refill is not observed in
this fourth month). Similarly, a 1-month period prior to the date of survey return postmark was
observed to account for potential overlaps in fills or refills from that period. Based on the NCQA
specifications, only participants that had drug coverage for a minimum of 60 days were included
in this analysis. This file was further converted into a patient-level file, and the therapeutic
category-specific PDCs were averaged to calculate patient-specific mean PDC scores. This file
was used for data analysis.

Data Analysis
Data were analyzed using SAS 9.4. This study utilized the survey data collected in the
study by Athavale et al, in their development of the MNAS.64 Results of confirmatory factor
analysis, and the subsequent internal consistency reliability, and convergent and discriminant
validity analyses conducted using these data have been elaborately explained by the authors in
their paper titled ‘Development of the Medication Non-Adherence Scale (MNAS) and the
Medication Non-Persistence Scale (MNPS)’64. In order to meet the first objective of this study –
predictive validation of the MNAS – two multivariable linear regressions were conducted using
the GLM procedure in SAS. In the first model, the summated MNAS sub-scales were used as
independent variables, important demographic variables§ as control variables, and the patient-
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specific mean PDC variable as the dependent variable. In the second model, the MNAS sub-scale
scores were replaced with the overall summated MNAS score.
To calculate sensitivity and specificity of the MNAS while predicting future medication
non-adherence, the score on the scale was first divided into meaningful categories. This was
done by constructing a receiver-operating characteristic (ROC) curve for the overall summated
MNAS score. The patient-specific mean PDC variable was converted to a dichotomous
adherence variable, assuming that patients with a score of 95% or above are adherent to their
medications**, and used in the ROC curve analysis. The optimum cut-off point thus determined
was used to calculate sensitivity and specificity.
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RESULTS

Sample Demographic Characteristics
The sample frame contained 4,554 patients. After 40 days in the field, 831 completed
survey responses were obtained, and 611 packets were returned by the postal service due to
incomplete or outdated mailing addresses. Thus, a response rate of 21.08% was observed. Upon
joining this file with the prescription fill data, and creating a patient-level file by averaging the
therapeutic category-specific PDCs, 579 patients remained in the final sample used for analysis.
Details about the sample used in this study can be viewed in Table 1. The inclusion
criteria required the consumption of at least one prescription medication indicated for diabetes,
hypertension, or dyslipidemia. Thus the average age of the sample was 65 years, and 64.1% of
individuals were greater than 60 years of age. The sample was 57.3% female, 86.4% white, with
64.8% indicating that they were currently married. About 24% indicated that they were college
educated. About half the sample indicated that they earned less than $40,000. About 65% of the
sample indicated that they consumed 3-8 chronic medications, with at least one of them
prescribed for diabetes, hypertension, or dyslipidemia. More than 50% of the sample were
insured by Medicare, private insurance, or both, and about 90% indicated that they would
classify their health status as from ‘very good’ to ‘fair’.
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Predictive Validity of the MNAS
As described earlier, two multivariable regression models were conducted to assess the
predictive validity of the MNAS. The results of both models can be viewed in Table 2. The first
model contained the five MNAS sub-scale scores as independent variables. The results of this
model identified a statistically significant association between three MNAS sub-scales and the
adapted NCQA patient-specific mean PDC measure – intentional non-adherence due to worries
about medication cost (unstandardized regression coefficient = -1.17 (p = 0.02)), intentional nonadherence due to lack of perceived need of the medication (unstandardized regression coefficient
= -0.75 (p < 0.05)), and unintentional non-adherence (unstandardized regression coefficient = 0.65 (p = 0.01)). The regression estimates indicated that a higher score on the sub-scales was
associated with a lower PDC value, which was the expected direction. The second regression
model utilized an overall summated MNAS score rather than the sub-scale scores. This model
found evidence for a statistically significant association between such a summated score and the
adapted NCQA PDC measure (unstandardized regression coefficient = -0.62 (p < 0.01)). The
results of these two models provided the necessary evidence to conclude that the MNAS has
predictive validity with the adapted NCQA PDC measure.

Optimum Cut-off Point, Sensitivity, and Specificity
A ROC curve was plot using the LOGISTIC procedure in SAS 9.4 to arrive at an
optimum cut-off point for the MNAS when estimating future medication non-adherence. A c
statistic of 0.63 was obtained. The top five Youden’s J values were assessed by comparing the
resultant sensitivity, specificity, false positive, and false negative values generated. Considering
that identifying a case of non-adherence (though at times incorrectly) is more important than
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excluding adherent individuals, a decision was made to favor sensitivity over specificity, and a
score of 20.7 on the overall summated MNAS was considered the optimal cut-off point. At this
point, the scale had a sensitivity of 0.78 and specificity of 0.41. As the overall summated MNAS
scale score can only be in the form of whole numbers, and for ease of interpretation in a practice
setting, a cut-off point of 20 was finalized. At this point, the scale had a sensitivity of 0.72 and
specificity of 0.48.
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DISCUSSION

A review of the literature conducted by the authors identified five scales that were disease
non-specific, and designed to offer an estimate of future medication non-adherence behavior –
Adherence 14 (A14) scale29, Adherence Starts and Knowledge-20 (ASK-20) scale35, th Medical
Adherence Measure (MAM)42, Beliefs and Behaviour Questionnaire (BBQ)47, and Adherence
Estimator® (AE)48–50. But out of these, only the AE has been previously tested for its predictive
validity.48–50 Also, despite having favorable psychometric properties, the AE leaves a few
reasons for non-adherence unmeasured. Due to such a limited spectrum of reasons, appropriate
tailoring of interventions to improve medication adherence may be hampered.
The Medication Non-Adherence Scale (MNAS) has also demonstrated good
psychometric properties, has been designed to be disease non-specific, and has been shown to
distinguish between five reasons for non-adherence – intentional non-adherence due to worries
about side-effects, intentional non-adherence due to worries about addiction to the medication,
intentional non-adherence due to worries about cost of the medication, intentional non-adherence
due to lack of perceived need for the medication, and unintentional non-adherence.64 This paper
provides evidence for the use of the MNAS as an instrument to predict future medication nonadherence. This scale has also been concurrently validated to estimate a 6-month measure of
PDC.14,64,65,68 Thus by demonstrating the ability of the MNAS in predicting both, concurrent and

119

future medication non-adherence, the evidence presented in this paper further improves the
applicability of the scale in a practice setting.

Interpretation for Results and Recommendations for Use in Practice
Out of the MNAS sub-scales, those concerned with worries about medication cost, lack
of perceived need, and unintentional non-adherence, were seen to have a statistically significant
impact on future medication non-adherence. When the 3-month measure of future PDC was
regressed on the overall summated MNAS, it was observed that on average, for every 1 unit
increase in the MNAS score, the PDC percentage decreased by 0.61 percent. Further, the ROC
curve analysis revealed that on average a score beyond 20 on the MNAS estimated a PDC below
95%. If a patient presents with such a score, his/her sub-scale responses must be considered to
determine the type of intervention that is needed to improve medication adherence. Higher score
on the unintentional non-adherence sub-scale will require reminders (SMS, email, phone call,
etc.) to improve their adherence, while higher scores on the other sub-scales may require patient
counselling to deal with the specific issue(s) at hand. If worries of medication cost is the primary
driver of the overall summated MNAS score, either switching to cheaper generics, redirection to
cost-saving programs from pharmaceutical companies, or patient counselling to improve the
patient’s understanding of the importance of medication may be necessary.

Limitations of the Scale and Directions for Future Research
The first limitation of the present study is the potentially low external validity of the
results. This study was conducted among patrons of three independent community pharmacies in
the Southeastern region of the United States. Though the results presented here depict a robust
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association between the scale and the objective measure of medication non-adherence used, the
authors cannot make any claims about its applicability in other geographic and demographic
settings. Future studies must assess the applicability of this scale in other samples to improve its
validity.
Athavale et al presented an elaborate account of pretests conducted to try and ensure the
inclusion of all reasons for medication non-adherence.64 They also noted the absence of any
evidence of socially desirable response bias in the measure.64 But the analysis conducted here
indicates that the scale only explains 11.12% of the variation in future non-adherence. One
reason for such a result may be found in the work published by Cole and colleagues.71,72 They
state that most psychological constructs are composed of three components – state, trait, and
occasion. In testing whether past behavior can predict future behavior, the current paper may
only have estimated the ‘trait’ component of medication adherence; the unexplained variation in
future PDC may be estimated by appropriately extracting the ‘state’ and ‘occasion’ components
of the construct. Future research should test such a hypothesis to improve the self-reported
measurement of medication adherence.
Finally, though this study validates the MNAS using a generally accepted objective
measure of medication adherence, it is necessary for future studies to comparatively assess the
ability of other contemporary scales, particularly the Adherence Estimator® (AE)49, in predicting
future PDC. Such an assessment will help establish a superior scale for this purpose.

Conclusion
The Medication Non-Adherence Scale (MNAS) has been demonstrated to estimate
concurrent64 as well as future medication non-adherence, and distinguish between different
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reasons for the same in a disease non-specific context64. On account of its validation against the
proportion of days covered (PDC) measure of medication adherence, it may offer health care
practitioners a tool for enhancing their reimbursement from payers.†† Thus, the results elucidated
by Athavale et al in their development of the MNAS64 and those presented here, build a
compelling argument for the use the MNAS in health care practice and research.

122

BIBLIOGRAPHY

123

1.

Elliott R. Non-adherence to medicines: not solved but solvable. J Health Serv Res Policy
[Internet]. 2009 Jan [cited 2012 Jul 12];14(1):58–61. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/19103918

2.

Frazee S, Miller S, Nease R, Stettin G. Express Scripts 2011 Drug Trend Report. St.
Louis, Missouri; 2012 p. 1–188.

3.

Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, et al. Effect
of medication nonadherence on hospitalization and mortality among patients with diabetes
mellitus. Arch Intern Med [Internet]. 2006 Sep 25;166(17):1836–41. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/17000939

4.

Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, et al. Impact of
medication therapy discontinuation on mortality after myocardial infarction. Arch Intern
Med [Internet]. 2006 Sep 25;166(17):1842–7. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/17000940

5.

Horne R, Weinman J, Barber N, Elliott R, Morgan M, Cribb A, et al. Concordance,
Adherence and Compliance in Medicine Taking: Report for the National Co-ordinating
Centre for NHS Service Delivery and Organisation R & D (NCCSDO). Southampton,
UK; 2005 p. 129.

6.

Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence
on hospitalization risk and healthcare cost. Med Care [Internet]. 2005 Jun;43(6):521–30.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/15908846

124

7.

Osterberg L, Blaschke T. Adherence to medication. N Engl J Med [Internet]. 2005 Aug
4;353(5):487–97. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16079372

8.

Vik SA, Maxwell CJ, Hogan DB. Measurement, correlates, and health outcomes of
medication adherence among seniors. Ann Pharmacother [Internet]. 2004 Feb [cited 2012
Mar 28];38(2):303–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14742770

9.

Farmer KC. Methods for measuring and monitoring medication regimen adherence in
clinical trials and clinical practice. Clin Ther. 1999;21(6):1074–90.

10.

Garfield S, Clifford S, Eliasson L, Barber N, Willson A. Suitability of measures of selfreported medication adherence for routine clinical use: a systematic review. BMC Med
Res Methodol [Internet]. BioMed Central Ltd; 2011 Jan [cited 2012 Mar 31];11(1):149–
57. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3219622&tool=pmcentrez&re
ndertype=abstract

11.

Spiker B. Methods of assessing and improving patient compliance in clinical trials. IRB
Ethics Hum Res. 1992;14(3):1–6.

12.

Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. An empirical basis for
standardizing adherence measures derived from administrative claims data among diabetic
patients. Med Care. 2008;46:1125–33.

13.

Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Prospective validation
of eight different adherence measures for use with administrative claims data among

125

patients with schizophrenia. Value Heal [Internet]. 2009 Sep;12(6):989–95. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/19402852

14.

Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy
administrative databases: a proposal for standard definitions and preferred measures. Ann
Pharmacother [Internet]. 2006 [cited 2012 Jul 21];40(7-8):1280–8. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/16868217

15.

Zeller A, Schroeder K, Peters TJ. Electronic pillboxes (MEMS) to assess the relationship
between medication adherence and blood pressure control in primary care. Scand J Prim
Health Care [Internet]. 2007 Dec [cited 2012 Jul 18];25(4):202–7. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3379760&tool=pmcentrez&re
ndertype=abstract

16.

Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication
taken as prescribed? A novel assessment technique. J Am Med Assoc [Internet]. 1989
Jan;261:3273–7. Available from:
http://linkinghub.elsevier.com/retrieve/pii/0959804993920835

17.

Rudd P, Ahmed S, Zachary V, Barton C, Bonduelle D. Improved compliance measures:
applications in an ambulatory hypertensive drug trial. Clin Pharmacol Ther [Internet].
1990 Dec;48(6):676–85. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2147405

18.

Nunes V, Neilson J, O’Flynn N, Calvert N, Kuntze S, Smithson H, et al. Clinical
Guidelines and Evidence Review for Medicines Adherence: involving patients in
decisions about prescribed medicines and supporting adherence. London, UK; 2009.
126

19.

Morisky DE, Green LW, Levine DM. Concurrent and predictive validty of a self-reported
measure of medication adherence. Med Care. 1986;24(1):67–74.

20.

Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication
Adherence Rating Scale (MARS) for the psychoses. Schizophr Res [Internet]. 2000 May
5;42(3):241–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10785582

21.

Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief Medication Questionnaire:
a tool for screening patient adherence and barriers to adherence. Patient Educ Couns
[Internet]. 1999 Jun;37(2):113–24. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/14528539

22.

Byerly MJ, Nakonezny PA, Rush AJ. The Brief Adherence Rating Scale (BARS)
validated against electronic monitoring in assessing the antipsychotic medication
adherence of outpatients with schizophrenia and schizoaffective disorder. Schizophr Res
[Internet]. 2008 Mar [cited 2012 Jul 18];100(1-3):60–9. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/18255269

23.

Morisky DE, Ang A, Krousel-Wood M. Predictive validity of a medication adherence
measure in an outpatient setting. J Clin Hypertens. 2009;10(5):348–54.

24.

Unni EJ, Farris KB. Development of a new scale to measure self-reported medication
nonadherence. Res Soc Adm Pharm [Internet]. Elsevier Inc; 2009; Available from:
http://dx.doi.org/10.1016/j.sapharm.2009.06.005

127

25.

Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in
schizophrenics: reliability and discriminative validity. Psychol Med [Internet]. 1983 [cited
2013 Apr 18];13(01):177–83. Available from:
http://journals.cambridge.org/abstract_S0033291700050182

26.

Kim MT, Hill MN, Bone LR, Levine DM. Development and Testing of the Hill-Bone
Compliance to High Blood Pressure Therapy Scale. Prog Cardiovasc Nurs [Internet]. 2000
Jun [cited 2013 Apr 18];15(3):90–6. Available from: http://doi.wiley.com/10.1111/j.17517117.2000.tb00211.x

27.

Dolder CR, Larco JP, Warren KA, Golshan S, Perkins DO, Jeste D V. Brief evaluation of
medication influences and beliefs: development and testing of a brief scale for medication
adherence. J Clin Psychopharmacol [Internet]. 2004;24(4):404–9. Available from:
http://journals.lww.com/psychopharmacology/Abstract/2004/08000/Brief_Evaluation_of_
Medication_Influences_and.8.aspx

28.

Highstein GR, Willey C, Mundy LM. Development of Stage of Readiness and decisional
balance instruments: tools to enhance clinical decision-making for adherence to
antiretroviral therapy. AIDS Behav [Internet]. 2006 Sep [cited 2013 Apr 18];10(5):563–
73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16552624

29.

Jank S, Bertsche T, Schellberg D, Herzog W, Haefeli WE. The A14-scale: development
and evaluation of a questionnaire for assessment of adherence and individual barriers.
Pharm World Sci [Internet]. 2009 Aug [cited 2013 Apr 18];31(4):426–31. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/19381860

128

30.

De Klerk E, van der Heijde D, van der Tempel H, van der Linden S. Development of a
questionnaire to investigate patient compliance with antirheumatic drug therapy. J
Rheumatol [Internet]. 1999 Dec 1 [cited 2013 Apr 18];26(12):2635–41. Available from:
http://europepmc.org/abstract/MED/10606375/reload=0

31.

Girerd X, Hanon O, Anagnostopoulos K, Ciupek C, Mourad JJ, Consoli S. [Assessment of
antihypertensive compliance using a self-administered questionnaire: development and
use in a hypertension clinic]. Presse Med [Internet]. 2001 Jan 16 [cited 2013 Apr
18];30(21):1044–8. Available from: http://europepmc.org/abstract/MED/11471275

32.

Girerd X, Radauceanu A, Achard JM, Fourcade J, Tournier B, Brillet G, et al. [Evaluation
of patient compliance among hypertensive patients treated by specialists]. Arch Mal Coeur
Vaiss [Internet]. 2001 Aug [cited 2013 Apr 18];94(8):839–42. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/11575214

33.

Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to
antiretroviral therapy are consistent with electronic data and virological treatment
outcome. AIDS [Internet]. 2002 [cited 2013 Apr 18];16(2):269–77. Available from:
http://journals.lww.com/aidsonline/Abstract/2002/01250/Responses_to_a_1_month_self_r
eport_on_adherence_to.17.aspx

34.

Pawin H, Beylot C, Chivot M, Faure M, Poli F, Revuz J, et al. Creation of a tool to assess
adherence to treatments for acne. Dermatology [Internet]. 2009 Jan [cited 2013 Apr
18];218(1):26–32. Available from: http://www.karger.com/Article/Fulltext/165628

129

35.

Hahn SR, Park J, Skinner EP, Yu-Isenberg KS, Weaver MB, Crawford B, et al.
Development of the ASK-20 adherence barrier survey. Curr Med Res Opin [Internet].
2008 Jul [cited 2013 Apr 18];24(7):2127–38. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/18554431

36.

Prado-Aguilar CA, Martínez Y V, Segovia-Bernal Y, Reyes-Martínez R, Arias-Ulloa R.
Performance of two questionnaires to measure treatment adherence in patients with type-2
diabetes. BMC Public Health [Internet]. 2009 Jan [cited 2013 Mar 1];9:38–46. Available
from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2637241&tool=pmcentrez&re
ndertype=abstract

37.

Kennedy SB. Developing a self-administered tool to predict adherence to antiretroviral
therapy: design, method, and objectives. AIDS Patient Care STDS [Internet]. 2000
Jun;14(6):309–16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10897503

38.

Mathews WC, Mar-Tang M, Ballard C, Colwell B, Abulhosn K, Noonan C, et al.
Prevalence, predictors, and outcomes of early adherence after starting or changing
antiretroviral therapy. AIDS Patient Care STDS [Internet]. 2002 Apr;16(4):157–72.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/12015870

39.

Martín J, Escobar I, Rubio R, Sabugal G, Cascón J, Pulido F. Study of the validity of a
questionnaire to assess the adherence to therapy in patients infected by HIV. HIV Clin
Trials. 2001;2(1):31–7.

130

40.

Schoberberger R, Janda M, Pescosta W, Sonneck G. The COMpliance Praxis Survey
(COMPASS): a multidimensional instrument to monitor compliance for patients on
antihypertensive medication. J Hum Hypertens [Internet]. 2002 Nov [cited 2013 Apr
18];16(11):779–87. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12444539

41.

Walewski KM, Cicutto L, D’Urzo AD, Heslegrave RJ, Chapman KR. Evaluation of a
questionnaire to assess compliance with anti-asthma medications. J Asthma [Internet].
2004 Jan [cited 2013 Apr 18];41(1):77–83. Available from:
http://informahealthcare.com/doi/abs/10.1081/JAS-120026064

42.

Zelikovsky N, Schast AP. Eliciting accurate reports of adherence in a clinical interview:
development of the Medical Adherence Measure. Pediatr Nurs [Internet]. 2008;34(2):141–
6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18543839

43.

Zeller A, Schroeder K, Peters TJ. An adherence self-report questionnaire facilitated the
differentiation between nonadherence and nonresponse to antihypertensive treatment. J
Clin Epidemiol [Internet]. 2008 Mar [cited 2013 Apr 18];61(3):282–8. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/18226752

44.

Kampman O, Lehtinen K, Lassila V, Leinonen E, Poutanen O, Koivisto A. Attitudes
towards neuroleptic treatment: reliability and validity of the attitudes towards neuroleptic
treatment (ANT) questionnaire. Schizophr Res [Internet]. 2000 Oct 27;45(3):223–34.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/11042440

131

45.

Weiden P, Rapkin B, Mott T, Zygmunt A, Goldman D, Horvitz-Lennon M, et al. Rating
of medication influences (ROMI) scale in schizophrenia. Schizophr Bull [Internet]. 1994
Jan;20(2):297–310. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7916162

46.

Balfour L, Tasca GA, Kowal J, Corace K, Cooper CL, Angel JB, et al. Development and
validation of the HIV Medication Readiness Scale. Assessment [Internet]. 2007 Dec [cited
2013 Apr 18];14(4):408–16. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/17986658

47.

George J, Mackinnon A, Kong DCM, Stewart K. Development and validation of the
Beliefs and Behaviour Questionnaire (BBQ). Patient Educ Couns [Internet]. 2006 Dec
[cited 2013 Apr 18];64(1-3):50–60. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/16843634

48.

Gadkari A, McHorney C. PHP2: Validity of the Adherence Estimator in the prediction of
persistence with chrnonic medications assessed over 14 months. ISPOR 15th Annual
International Meeting [Internet]. Atlanta, GA: International Society for
Pharmacoeconomics and Outcomes Research (ISPOR); 2010 [cited 2013 Apr 17].
Available from: http://linkinghub.elsevier.com/retrieve/pii/S1098301510723858

49.

McHorney CA. The Adherence Estimator: a brief, proximal screener for patient
propensity to adhere to prescription medications for chronic disease. Curr Med Res Opin
[Internet]. 2009 Jan [cited 2012 Oct 5];25(1):215–38. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/19210154

132

50.

McHorney CA, Victor Spain C, Alexander CM, Simmons J. Validity of the adherence
estimator in the prediction of 9-month persistence with medications prescribed for chronic
diseases: a prospective analysis of data from pharmacy claims. Clin Ther [Internet].
Excerpta Medica Inc.; 2009 Nov [cited 2013 Apr 17];31(11):2584–607. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/20110004

51.

Unni EJ, Olson JL, Farris KB. Revision and validation of Medication Adherence Reasons
Scale (MAR-Scale). Curr Med Res Opin [Internet]. Informa UK Ltd. London; 2013 Oct
30 [cited 2013 Oct 15];1–11. Available from:
http://informahealthcare.com/doi/abs/10.1185/03007995.2013.851075?journalCode=cmo

52.

Willey C, Redding C, Stafford J, Garfield F, Geletko S, Flanigan T, et al. Stages of change
for adherence with medication regimens for chronic disease: development and validation
of a measure. Clin Ther [Internet]. 2000 Jul;22(7):858–71. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/10945512

53.

Lowry KP, Dudley TK, Oddone EZ, Bosworth HB. Intentional and unintentional
nonadherence to antihypertensive medication. Ann Pharmacother [Internet]. 2005 [cited
2012 Jul 22];39(7-8):1198–203. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/15956238

54.

Wroe AL. Intentional and unintentional nonadherence: a study of decision making. J
Behav Med [Internet]. 2002 Aug;25(4):355–72. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/12136497

133

55.

Barber N. Should we consider non-compliance a medical error? Qual Saf Health Care
[Internet]. 2002 Mar;11(1):81–4. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1743570&tool=pmcentrez&re
ndertype=abstract

56.

Barber N, Safdar A, Franklin BD. Can human error theory explain non-adherence? Pharm
World Sci [Internet]. 2005 Aug;27(4):300–4. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/16228628

57.

Horne R. Compliance, adherence, and concordance: implications for asthma treatment.
Chest [Internet]. 2006 Jul 1 [cited 2012 Jul 22];130(1 Suppl):65S – 72S. Available from:
http://journal.publications.chestnet.org/article.aspx?articleid=1210785

58.

Iihara N, Kurosaki Y, Miyoshi C, Takabatake K, Morita S, Hori K. Comparison of
individual perceptions of medication costs and benefits between intentional and
unintentional medication non-adherence among Japanese patients. Patient Educ Couns
[Internet]. 2008 Feb [cited 2012 Jul 22];70(2):292–9. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/18068938

59.

Lehane E, McCarthy G. Intentional and unintentional medication non-adherence: a
comprehensive framework for clinical research and practice? A discussion paper. Int J
Nurs Stud [Internet]. 2007 Nov [cited 2012 Jul 22];44(8):1468–77. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/16973166

60.

Lehane E, McCarthy G. An examination of the intentional and unintentional aspects of
medication non-adherence in patients diagnosed with hypertension. J Clin Nurs [Internet].
134

2007 Apr [cited 2012 Jul 22];16(4):698–706. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/17402951

61.

Schüz B, Marx C, Wurm S, Warner LM, Ziegelmann JP, Schwarzer R, et al. Medication
beliefs predict medication adherence in older adults with multiple illnesses. J Psychosom
Res [Internet]. Elsevier Inc.; 2011 Feb [cited 2012 Jul 22];70(2):179–87. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/21262421

62.

Bosworth HB, Voils CI. Theoretical models to understand treatment adherence. In:
Bosworth HB, Oddone EZ, Weinberger M, editors. Patient Treatment Adherence:
Concept, Interventions and Measurement. 1st ed. Mahwah, NJ: Lawrence Erlbaum
Associates; 2006. p. 13–47.

63.

Lorig KR, Sobel DS, Ritter PL, Laurent D, Hobbs M. Effect of a self-management
program on patients with chronic disease. Eff Clin Pract. 2001;4(6):256–62.

64.

Athavale AS, Bentley JP, Banahan III BF, McCaffrey DJ, Vorhies DW. Development of
the Medication Non-Adherence Scale (MNAS) and the Medication Non-Persistence Scale
(MNPS). [University, MS]: The University of Mississippi; 2015. p. 49.

65.

National Committee for Quality Assurance. Pharmacy Measures. 2010 p. 9–17.

66.

Reason J. Human error: models and management. Br Med J. 2000;320:768–70.

67.

Reason J. Understanding adverse events: human factors. Qual Heal Care. 1995;4:80–9.

135

68.

Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term
persistence in use of statin therapy in elderly patients. J Am Med Assoc [Internet].
2002;288(4):455–61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12132975

69.

Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental
evaluation tool in clinical medicine. Clin Chem. 1993;39(4):561–77.

70.

Metz CE. Basic principles of ROC analysis. Semin Nucl Med. 1978;VIII(4):283–98.

71.

Olatunji BO, Cole DA. The longitudinal structure of general and specific anxiety
dimensions in children: testing a latent trait-state-occasion model. Psychol Assess
[Internet]. 2009 Sep [cited 2013 Dec 8];21(3):412–24. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/19719352

72.

Cole DA, Martin NC, Steiger JH. Empirical and conceptual problems with longitudinal
trait-state models: introducing a trait-state-occasion model. Psychol Methods [Internet].
2005 Mar [cited 2012 Oct 5];10(1):3–20. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/15810866

73.

Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, et al.
Treatment of COPD: relationships between daily dosing frequency, adherence, resource
use, and costs. Respir Med [Internet]. Elsevier Ltd; 2011 Mar [cited 2013 May
21];105(3):435–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20880687

74.

Nau DP. Proportion of days covered (PDC) as a preferred method of measuring
medication adherence [Internet]. Pharmacy Quality Alliance (PQA). 2009 [cited 2013 Feb

136

10]. p. 1–3. Available from: http://www.pqaalliance.org/images/uploads/files/PQA PDC
vs MPR.pdf

75.

Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor
adherence: optimal cut-point for adherence measures using administrative claims data.
Curr Med Res Opin [Internet]. 2009 Sep [cited 2012 Mar 20];25(9):2303–10. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/19635045

76.

Centers for Medicare & Medicaid Services. Announcement of Calendar Year (CY) 2013
Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment
Policies and Final Call Letter. 2012. p. 1–160.

137

LIST OF APPENDICES

138

APPENDIX A

139

Table 1
Description of sample demographic characteristics
Demographic Characteristics

Age

Gender

140
Race

Education

Marital Status

#

%

<= 45

34

5.9%

46 – 60

174

30.1%

61 – 70

172

29.7%

71 – 80

136

23.5%

> 80

63

10.9%

Male

190

32.8%

Female

332

57.3%

Missing

57

9.8%

White

500

86.4%

Other races

76

13.1%

Missing

3

0.5%

Up to high school graduate

240

41.5%

Some college (no degree), trade or technical school, or associate degree

192

33.2%

Bachelors, professional, or graduate degree

142

24.5%

Missing

5

0.9%

Married

375

64.8%

Currently not married

203

34.8%

1

0.2%

150

25.9%

Missing
Income

Under $20,000

No. of Medications

141
Health Insurance

Health Status

$20,000 to $39,999.99

132

22.8%

$40,000 to $59,999.99

82

14.2%

$60,000 to $79,999.99

56

9.7%

$80,000 or more

117

20.2%

Missing

42

7.3%

1–2

60

10.4%

3–4

139

24.0%

5–6

143

24.7%

7–8

97

16.8%

9 – 10

50

8.6%

> 10

69

11.9%

Missing

21

3.6%

Medicare

339

50.2%

Medicaid

66

9.8%

Private

364

53.9%

Uninsured

33

4.9%

Tricare

6

0.9%

Don’t know

6

0.9%

Missing

4

0.6%

Excellent

16

2.8%

Very Good

137

23.7%

Good

229

39.6%

Fair

158

27.3%

Poor

37

6.4%

Missing

2

0.3%
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Table 2
Predictive validation of the Medication Non-Adherence Scale
Dependent variable: Participants-specific mean PDC
Parameter

Estimatec

Std. Error

p-value

Model with MNAS sub-scale scores as independent variables (R2 = 0.1112)

144

Intercept

96.12

3.84

<0.01

MNAS-I-Side-effects

-0.53

0.39

0.18

MNAS-I-Addiction

0.50

0.81

0.54

MNAS-I-Cost

-1.17

0.50

0.02

MNAS-I-Need

-0.75

0.37

<0.05

MNAS-U

-0.65

0.25

0.01

Model with overall MNAS score as independent variable (R2 = 0.1058)
Intercept

96.16

3.82

<0.01

MNAS

-0.61

0.10

<0.01

c

The estimates have been adjusted for age and race.

*

This study uses the survey data collected in the paper by Athavale et al64. For a detailed explanation of the survey
data collection methodology, please refer to their article titled ‘Development of the Medication Non-Adherence
Scale (MNAS) and the Medication Non-Persistence Scale (MNPS)’.
†
Studies by Toy et al.73 and Benner et al.68 have assessed adherence at 3 months using PDCs. While Toy et al.
concluded that in the case of a once-daily dose, the level of adherence does not change over time, Benner concluded
that the PDC value decreases over time.
‡
The MID was linked to the PTID, and was printed on each survey instrument. It was used to mask the survey
responses from the independent data manager. The researchers possessed the crosswalk between the MID and the
PTID, while the independent data manager possessed the crosswalk between the PTID and patients’ names and
addresses.
§
A series of univariable linear regressions were conducted using the patient-specific mean PDC as the dependent
variable and each measured demographic variable as an independent variable. Variables that demonstrated a
statistically significant relationship with the DV were termed ‘important demographic variables’.
**
A cut-off point of 95% was used rather than the traditional 80% 68,74,75 based on the MNAS item wording.
††
Proportion of days covered (PDC) is used by the Centers of Medicare & Medicaid (CMS)76, and many private
insurers to determine pharmacy use quality, which in turn is used to determine reimbursement.
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ABSTRACT

Background
There are numerous self-reported measures to estimate medication adherence. The Medication
Non-Adherence Scale (MNAS) has offered promising results in estimating concurrent and future
medication non-adherence.
Objective
To compare the ability of the MNAS, 1986 Morisky scale, and Medication Adherence Reasons
Scale in estimating concurrent medication adherence, and the MNAS and Adherence Estimator®
in estimating future medication adherence.
Methods
An observational study with retrospective and prospective phases was conducted among patrons
of three independent community pharmacies in the Southeastern United States. A survey
containing the scales to be assessed was administered to patients that have filled medications
indicated for diabetes, hypertension, and/or dyslipidemia. The survey data were then linked to
the patients’ prescription fill data. Univariable linear regressions were conducted using each
scale as the independent variable, and the appropriate proportion of days covered (PDC) variant
(6-month retrospective or 3-month prospective) as the dependent variable. The statistical
significance (at α = 0.05), standardized regression coefficients, and R2s were compared, and the
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predicted values generated from each regression were used to assess whether the estimates
generated by each scale are statistically significantly different from each other.
Results
In estimating concurrent PDC, the MNAS model generated an R2 of 0.043, and a standardized
regression coefficient of -0.208, the Morisky scale model generated an R2 of 0.018, and a
standardized regression coefficient of -0.134, and the MAR-Scale model generated an R2 of
0.016, and a standardized regression coefficient of -0.125. In estimating future PDC, MNAS
model generated an R2 of 0.083, and a standardized regression coefficient of -0.288, the AE
model generated an R2 of 0.010, and a standardized regression coefficient of -0.099. Both
relationships were found to be statistically significant. All estimates were also found to be
statistically significantly different from those generated by the MNAS.
Conclusions
The MNAS was observed to perform better in estimating concurrent and future medication
adherence than the comparator scales.
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INTRODUCTION

The negative impact of medication non-adherence has been studied extensively. The
resultant health-related and economic adverse effects have been demonstrated in a wide range of
chronic diseases such as hypertension, diabetes, hypercholesterolemia, congestive heart failure,
and myocardial infarction.1–5 Numerous interventions have been devised to counter the issue of
medication non-adherence.6–13 But in order to implement a successful intervention, effective
measurement of the construct is necessary.
A meta-analysis conducted by Peterson and colleagues concluded that most medication
adherence interventions occurred in a practice setting.8 According to the National Collaborating
Centre for Primary Care and the Royal College of General Practitioners (London, UK), and the
National Institute of Health and Clinical Excellence (NICE), self-reported questionnaires are best
suited for measuring and identifying medication non-adherence in this setting.14 This point is
also supported by Garfield and colleagues at the British Medical Association.15 A number of
self-reported instruments have been developed over the past few decades to measure concurrent
medication non-adherence, and predict the propensity of future non-adherence. These include the
1986 Morisky scale16, Medication Adherence Reasons Scale (MAR-Scale)17, Medication
Adherence Rating Scale (MARS)18, Brief Medication Questionnaire (BMQ)19, Brief Adherence
Rating Scale (BARS)20, Morisky Medication Adherence Scale21, Adherence 14 (A14) scale22,
Adherence Starts and Knowledge-20 (ASK-20) scale23, Medical Adherence Measure (MAM)24,
149

Beliefs and Behaviour Questionnaire (BBQ)25, Adherence Estimator® (AE)26–28 etc. Out of these
measures, the 1986 Morisky scale is the most prevalent in measuring concurrent medication nonadherence in health care practice and research.16,29–34 Its popularity is a result of its ability to be
used across multiple chronic diseases. It has been used in diseases like diabetes, hypertension,
HIV, fibromyalgia, cardiovascular diseases, etc.29,30,32–34 Despite its prevalence, it has offered
mixed results pertaining to internal consistency reliability.16,29–33 Morisky et al. published an
updated version of their scale in 2009 to overcome some of the downfalls of its predecessor.21
But the 2009 Morisky scale (Morisky Medication Adherence Scale) has twice the number of
items as the 1986 scale, and based on our literature review, has only been tested in the
hypertensive and diabetic populations.21,35–38
Recently, Unni and Farris developed the Medication Adherence Reasons Scale (MARScale) to help practitioners distinguish between the different reasons for non-adherence in the
dyslipidemia and asthma.17,39 This scale categorizes the reasons for non-adherence into four
factors – practicality issues (e.g. not being able to open the container, pharmacy being out of
medicine, etc.), lack of necessity belief issues (e.g. perceived need for medication, perceived
effectiveness of medication, etc.), concern belief issues (e.g. possible side-effects or long-term
effects), and forgetfulness issues. Though this scale has demonstrated respectable reliability and
validity, it is seen to perform differently across disease conditions17,39, and has only been
validated against self-reported, “subjective” measures17,40.
McHorney and colleagues developed the Adherence Estimator® (AE) in 2009.28 It is a
three-item scale designed to capture the proximal beliefs about intentional non-adherence.28 The
items measure perceived importance of medications, worries about adverse/side effects, and
perceived financial burden. These items have been validated for identification of individuals who
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have a propensity of being intentionally non-adherence to their medications in the future. The
results have demonstrated a promising ability to predict future intentional non-adherence. In
recent years, researchers have outlined the importance of assessing both, the intentional and
unintentional, components of medication non-adherence.15,34,41–49 The AE does not incorporate
the unintentional component of medication non-adherence, and based on the MAR-Scale, also
some aspects of the intentional component. It also has not been shown to yield valid, reliable, or
meaningful results across multiple medications.26,28
The Medication Non-Adherence Scale (MNAS) is a self-reported measure of medication
adherence which is designed to be practice setting administrable and disease non-specific.50 Its
ability to predict concurrent medication non-adherence has been tested in patients prescribed
medications for diabetes, hypertension, and dyslipidemia.50 It has presented with good
psychometric properties, and can distinguish between five reasons for medication non-adherence
– intentional non-adherence due to worries about side-effects, intentional non-adherence due to
worries about addiction to the medication, intentional non-adherence due to worries about
medication cost, intentional non-adherence due to lack of perceived need for the medication, and
unintentional non-adherence.50 There is also evidence to suggest that the MNAS can predict
future medication non-adherence over a 3-month period.51 Thus, the MNAS may help address
some of the issues presented by the 1986 Morisky scale, the MAR-Scale, and the AE.
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METHODOLOGY

Study Objectives and Study Design
A retrospective observational study was conducted among patrons of three independent
community pharmacies in the Southeastern region of the United States to compare the
Medication Non-Adherence Scale (MNAS) with the 1986 Morisky scale and the Medication
Adherence Reasons Scale (MAR-Scale), and a prospective observational study was conducted to
compare the MNAS with the Adherence Estimator®* (AE). The items on the MNAS can be
viewed in the appendix. The 1986 Morisky scale was chosen as a comparator while measuring
concurrent medication non-adherence, as it is the most widely used scale for this purpose.16,29–34
The MAR-Scale was also chosen as a comparator while measuring concurrent medication nonadherence as it takes a similar approach for assessing the reasons for medication non-adherence
as the MNAS, and has demonstrated good reliability and validity levels.17,39 The AE was chosen
as a comparator while measuring future medication non-adherence, as according to our review of
the literature, it is the only disease non-specific scale that has been tested for its predictive
validity against an objective measure.22–28 Specifically, this study had the following objectives:


To compare the ability of the MNAS and the 1986 Morisky scale in predicting
objectively measured concurrent medication non-adherence (using an adaptation of the
NCQA proportion of days covered (PDC) measure52,53)
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To compare the ability of the MNAS and the Medication Adherence Reasons Scale in
predicting objectively measured concurrent medication non-adherence (using an
adaptation of the NCQA proportion of days covered (PDC) measure52,53)



To compare the ability of the MNAS and the Adherence Estimator® in predicting
objectively measured future medication non-adherence (using an adaptation of the NCQA
proportion of days covered (PDC) measure52,53)

Sample Design and Data Collection
Prescription fill data for the past one year were obtained from three community
pharmacies in the Southeastern region of the US after Data Use Agreements (DUAs) were
approved and signed. Patients that were 18 years or older, and were prescribed at least one
medication indicated for diabetes, hypertension, or dyslipidemia were identified using an
encrypted patient ID (PTID) assigned by an independent data manager†. The researchers
specifically considered patients that started on one of seven therapeutic categories of interest
specified by the National Committee for Quality Assurance (NCQA)54 at least 6 months prior to
the end of data. These therapeutic categories include beta-blockers (BBs), angiotensin-converting
enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), calcium channel blockers
(CCBs), biguanides, sulfonylureas, thiazolidinediones, and statins.54 The independent data
manager then linked these PTIDs to patient names and addresses.
Survey instruments containing the MNAS, MNPS, a 5-point scale version of the 1986
Morisky Scale17,39,55,56, the MAR-Scale17, AE28, and demographic questions, printed on a
business reply mailers, were then printed for each patient in the sample frame. The survey
instrument also contained a unique mailing ID (MID) assigned by the researchers, which was
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patient specific, and linked to the PTID. The instrument was enclosed in an envelope with the
appropriate name, address, and MID printed on it. The MID was used to mask the survey data
from the independent data manager, and further protect patient privacy. After the receipt of
completed surveys, the three pharmacies were asked to amend the prescription fill data to 4
months after the end of the survey data collection period.

Data Management
The survey data were manually entered into a Microsoft Excel file, and then linked to the
prescription fill data using the MID and PTID such that there were 7 months of prescription fill
data prior to the date of survey return post-marking (concurrent period), and 4 months after
(predictive period).‡ These periods were patient-specific as the date of survey return post-mark
was different for each patient. Patients who did not respond to items on the MNAS, the 5-point
scale version of the 1986 Morisky scale, the MAR-Scale, were eliminated from the concurrent
period dataset. Those who did not respond to the MNAS and AE were eliminated from the
predictive period dataset. The past 6 months of prescription fill data were used to calculate the
proportion of days covered (PDC) measure for each of the seven therapeutic categories of
interest.52,57–59 A 6-month period was used in accordance with the recall period of the MNAS.
PDCs were also calculated on the 3-month period after the date of survey return post-mark.
Based on the NCQA guidelines for calculating PDCs, a minimum drug coverage of 90 days for
the concurrent period, and 60 days for the predictive period, was deemed appropriate.54 The
therapeutic category-specific concurrent and predictive period PDCs were then averaged to
calculate patient-specific mean concurrent and predictive period PDCs. As the number of
patients that met the minimum drug coverage period was expected to differ for the two periods,
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two separate analysis files were created, one for the concurrent period, and another for the
predictive period.

Data Analysis
SAS 9.4 was used for data analysis. In order to compare the MNAS and the 5-point 1986
Morisky scale in predicting concurrent medication non-adherence, two linear regressions were
conducted using the GLM procedure. The first model contained the overall summated MNAS
score as the independent variable and the patient-specific mean concurrent period PDC as the
dependent variable. The other model contained the adherence score obtained from the 5-point
1986 Morisky scale as the independent variable and the patient-specific mean concurrent period
PDC as the dependent variable. Upon running these analyses, statistical significance (at α =
0.05), standardized regression coefficients, and R2s obtained from the two models were
compared. The predicted values from the two regression models were saved into a separate SAS
dataset. The relative effectiveness of the two scales in predicting the patient-specific mean
concurrent period PDC was then statistically compared using the saved predicted values via the
procedure outlined by Steiger.60,61 The MNAS and the MAR-Scale were compared in a manner
identical to that mentioned above; the only difference being the replacement of the 5-point 1986
Morisky scale score with the score on the MAR-Scale.
The abilities of the MNAS and the Adherence Estimator® in predicting future medication
non-adherence were then compared. For this, two linear regressions were conducted. The prior
model included the overall MNAS score as independent variable and the patient-specific mean
predictive period PDC as the dependent variable. The latter model included a categorical version
of the score on the AE§ as the independent variable and the patient-specific mean predictive
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period PDC served as the dependent variable. The GLM procedure was used for these analyses.
The ordered categories in the AE variable were treated quantitatively for this analysis. The two
scales were then compared using the method explained in the preceding paragraph (i.e. while
comparing the MNAS and the 5-point 1986 Morisky scale).
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RESULTS

Sample Characteristics
The sample frame consisted of 4,554 patients. Survey instrument packets were created for
each of these patients, and mailed. At the end of a 40 day data collection period, 831 completed
responses were obtained. 611 packets were returned by the postal service due to improper
addresses. Thus a 21.08% response rate was observed (831 ÷ (4,554-611)). After joining the
prescription fill data to the data from the completed survey responses, the concurrent period file
contained 666 patients, while the predictive period file contained 567.
The samples consisted of an older demographic with 64.1% (in both samples) reporting
an age of greater than 60 years. About 30% of patients in either sample reported their age to be
between 46 and 60 years. Both samples had a greater proportion of females (56.3% in the
concurrent period sample and 57.3% in the predictive period sample), and about 87% reported
their race as ‘white’. Approximately 26% of the concurrent period sample and 24% of the
predictive period sample reported having at least a bachelor’s degree. About 65% in either
sample reported their marital status as ‘married’, and about 48% reported an annual household
income below $40,000. Approximately 65% of patients in both samples reported being
prescribed 3-8 medications for chronic conditions. Most patients were privately insured (61.9%
in the concurrent period and 53.1% in the predictive period), insured by Medicare (56.6% in the
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concurrent period and 49.5% in the predictive period), or by both. About 40% of patients in
either sample reported their general health status as being ‘good’.

Comparison with the 1986 Morisky Scale
In order to compare the 1986 Morisky scale with the MNAS, two regression models were
run. The MNAS model generated an R2 of 0.04, and a standardized regression coefficient of 0.21 while the Morisky scale model generated an R2 of 0.02, and a standardized regression
coefficient of -0.13. Relationships between the scales and the patient-specific mean concurrent
period PDC were found to be statistically significant at α = 0.05. These results can be viewed in
Table 2. The method proposed by Steiger60 was implemented to statistically compare the relative
effectiveness of the two scales in predicting the patient-specific mean concurrent period PDC.
The results of this analysis indicated that there was a statistically significant difference in the
relative effectiveness of the two scales (p = 0.01). Based on these results, the authors concluded
that the MNAS is more effective in estimating concurrent PDCs than the 1986 Morisky scale.

Comparison with the Medication Adherence Reasons Scale
The MAR-Scale and the MNAS were compared using two regression models. The results
of this comparison can be viewed in Table 2. The model with the overall summated MNAS score
generated a higher R2 value (0.04 versus 0.02 for the MAR-Scale) and a higher absolute value of
the standardized regression coefficient (0.21 versus 0.12 for the MAR-Scale). Both relationships
were found to be statistically significant at α = 0.05. Further, the two scales were compared using
the method outlined by Steiger.60 The results of this analysis indicated that the comparative
effectiveness of the two scales in predicting PDCs was statistically significantly different (p =
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0.03). Thus, these analysis indicate that the MNAS is more effective in estimating PDCs than the
MAR-Scale.

Comparison with the Adherence Estimator®
The MNAS was compared with the AE in predicting future medication non-adherence
measured using an adaptation of the NCQA PDC algorithm. This was done using two linear
regressions. The results of these regression models can be viewed in Table 2. The MNAS model
generated an R2 of 0.08, while the AE model generated an R2 of 0.01.** The relationship between
the overall summated MNAS score and the patient-specific mean predictive period PDC was
found to be statistically significant with a standardized regression coefficient of -0.29. The
relationship between the AE and the patient-specific mean predictive period PDC was also
observed to be statistically significant (at α = 0.05) with a standardized regression coefficient of 0.10. Also, when the effectiveness of the two scales in predicting PDCs was compared using the
method proposed by Steiger60, their predictive ability was statistically significantly different (p <
0.01). These analyses indicate that the MNAS is more effective in predicting patient-specific
mean predictive period PDCs than the AE.
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DISCUSSION

Medication non-adherence has been demonstrated to have detrimental health and
economic effects in a variety of chronic diseases – hypertension, diabetes, hypercholesterolemia,
congestive heart failure, and myocardial infarction.1–5 Due to the awareness of this impact,
numerous self-reported measured have been developed to estimate medication non-adherence,
both concurrently and predictively, in research and practice.16–25,28 The Medication NonAdherence Scale (MNAS) has demonstrated good internal consistency reliability, and
convergent and discriminant validity. Paper 1 and 2 also presented evidence for its concurrent
and predictive validity in estimating PDC. The purpose of the current paper was to assess the
comparative effectiveness of the MNAS and contemporary medication adherence, and
medication adherence propensity scales, in predicting concurrent and future PDCs, respectively.
The results presented here suggest that the MNAS performs better than the 5-point scale version
of the 1986 Morisky Scale17,39,55,56, the Medication Adherence Reasons Scale17, and Adherence
Estimator®28.

Interpretation of Results
The MNAS was observed to perform better in estimating PDCs in both periods. It offered
the highest R2 values – 0.04 in the concurrent period and 0.08 in the predictive period; it
explained 4.3% of the variation in patient-specific mean concurrent period PDC, and 8.3% of the
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variation in patient-specific mean predictive period PDC. The MNAS had a standardized
regression coefficient of -0.21 in the concurrent period and -0.29 in the predictive period. This
indicates that for every standard deviation unit increase in the MNAS scale score, the value of
the patient-specific mean PDC decreases by 0.21 standard deviation units in the concurrent
period, and 0.29 standard deviation units in the predictive period. This decrease was lesser in the
case of the comparator scales – 0.13 for the 5-point variant of the 1986 Morisky scale, 0.12 for
the MAR-Scale, and 0.04 for the Adherence Estimator®. Though the 1986 Morisky scale and the
MAR-Scale had inferior abilities to estimate mean PDC, these relationships were observed to be
statistically significant. The Adherence Estimator® also demonstrated a statistically significant
relationship with patient-specific mean predictive period PDC, but the MNAS offered higher
standardized regression coefficients and R2s. Furthermore, a comparison of the predictive
abilities of the scales using the method proposed by Steiger60 indicated that the estimates offered
by the MNAS were statistically significantly better than those offered by 1986 Morisky Scale
and MAR-Scale in predicting concurrent period PDCs, and those offered by the AE in predicting
predictive period PDCs.

Limitations of the Study and Directions for the Future
This study was conducted among patrons of three independent community pharmacies in
the Southeastern United States. This may limit the generalizability of the scale. Future
researchers should apply the MNAS in various socio-demographic and geographic settings to
assess its external validity. Though the current study is conducted among disease categories that
are of primary interest to health care providers and payers, MNAS should also be tested in other
disease conditions to further improve on its generalizability.
161

Though the MNAS performed better than the comparator scales, it is longer than the
1986 Morisky scale and the Adherence Estimator®, thus potentially more cumbersome to
administer. A shorter scale is usually desired in a practice setting. Thus future researchers should
develop ‘short-form’ variant of the MNAS to overcome this drawback of the scale.
Another observation that must be made based on the results presented here, is the low
values of R2 obtained for all self-reported measures in predicting PDCs. Considering the fact that
the scale underwent multiple rounds of qualitative and quantitative pretest evaluations prior to
this analysis minimizes the likelihood of the reason for such a result being unaccounted reasons
for medication non-adherence or socially desirable response bias.50 The authors believe that such
a result may have been observed due to a lack of items that measure medication non-adherence
due to over-dosing. PDC calculations not only account for gaps in fills, but also overlaps. Thus
accounting for such over-dosing may improve the amount of variation explained in PDC. Future
research should include an ‘over-dosing’ factor in the MNAS and reassess its concurrent and
predictive validity against PDC.

Conclusion
This paper presented a comparative estimation of an adaptation of the concurrently
measured National Committee for Quality Assurance (NCQA) proportion of days covered (PDC)
measure of medication adherence by the Medication Non-Adherence Scale (MNAS), a 5-point
version of the 1986 Morisky scale, and the Medication Adherence Reasons Scale (MAR-Scale).
Results of a comparative prediction of the adapted future PDC measure by the MNAS and the
Adherence Estimator® (AE) were also described here. These analyses provided evidence for the
statistical superiority of the MNAS in estimating both, concurrent and future, medication
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adherence (as measured by the adapted PDC measure), over the other scales used in this study.
Based on these results, and those obtained by Athavale et al in the MNAS developmental
papers50,51, the Medication Non-Adherence Scale offers health care practitioners and researchers
a valuable tool to improve patient health.
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Table 1
Description of sample demographic characteristics
Concurrent

Predictive

Period

Period

Demographic Characteristics

Age

174

Gender

Race

Education

Marital Status

#

%

#

%

<= 45

43

6.5%

34

5.9%

46 – 60

196

29.4%

174

30.1%

61 – 70

192

28.8%

172

29.7%

71 – 80

157

23.6%

136

23.5%

> 80

78

11.7%

63

10.9%

Male

223

33.5%

190

32.8%

Female

375

56.3%

332

57.3%

Missing

68

10.2%

57

9.8%

White

583

87.5%

500

86.4%

Other races

81

12.2%

76

13.1%

Missing

2

0.3%

3

0.5%

Up to high school graduate

270

40.5%

240

41.5%

Some college (no degree), trade or technical school, or associate degree

215

32.3%

192

33.2%

Bachelors, professional, or graduate degree

175

26.3%

142

24.5%

Missing

6

0.9%

5

0.9%

Married

431

64.7%

375

64.8%

Currently not married

234

35.1%

203

35.1%

Missing

Income

No. of Medications

175
Health Insurance

Health Status

1

0.2%

1

0.2%

Under $20,000

161

24.2%

150

25.9%

$20,000 to $39,999.99

161

24.2%

132

22.8%

$40,000 to $59,999.99

94

14.1%

82

14.2%

$60,000 to $79,999.99

64

9.6%

56

9.7%

$80,000 or more

141

21.2%

117

20.2%

Missing

45

6.8%

42

7.3%

1–2

83

12.5%

60

10.4%

3–4

165

24.8%

139

24.0%

5–6

165

24.8%

143

24.7%

7–8

108

16.2%

97

16.8%

9 – 10

55

8.3%

50

8.6%

> 10

67

10.1%

69

11.9%

Missing

23

3.5%

21

3.6%

Medicare

388

56.6%

339

49.5%

Medicaid

71

10.4%

66

9.6%

Private

424

61.9%

364

53.1%

Uninsured

37

5.4%

33

4.8%

Tricare

9

1.3%

6

0.9%

Don’t know

7

1.0%

6

0.9%

Missing

4

0.6%

4

0.6%

Excellent

20

3.0%

16

2.8%

Very Good

169

25.4%

137

23.7%

Good

265

39.8%

229

39.6%

Fair

171

25.7%

158

27.3%

Poor

39

5.9%

37

6.4%

Missing

2

0.3%

2

0.3%
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Table 2
Comparative effectiveness of the MNAS with contemporary scales
Scales
MNAS

Std. Reg.
Coef.

p value

0.04

-0.21

<0.01

0.02

-0.13

<0.01

MAR-Scale

0.02

-0.12

<0.01

MNAS

0.08

-0.29

<0.01

AE

0.01

-0.10

0.02

Concurrent Period 5-point 1986 Morisky Scale

Predictive Period

R2
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*

Adherence Estimator is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,
Whitehouse Station, NJ, USA. US and non-US Patents Pending. Copyright © 2008 Merck Sharp and Dohme Corp.,
a subsidiary of Merck & Co., Inc. All rights reserved.
†
This was done to ensure that patient identifiers were not exposed to the researchers, and to abide with Health
Insurance Portability and Accountability Act (HIPAA)62 regulations.
‡
Each month was assumed to be 30 days long.
§
This categorization was based on that proposed by McHorney28, where a score is ‘0’ is categorized as ‘low risk for
adherence problems’, ‘2-7’ as ‘medium risk for adherence problems’, and ‘8+’ as ‘high risk of adherence problems’.
**
This model was also run specifying the categorized Adherence Estimator® score as a categorical variable in the
model. This resulted in an R2 of 0.03.
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CHAPTER V:
DISCUSSION
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OVERVIEW

The purpose of this chapter is to discuss the findings and implications of this dissertation.
First, results of reliability and validity testing of the Medication Non-Adherence Scale (MNAS)
and the Medication Non-Persistence Scale (MNPS), and suggestions for their use in health care
practice, will be elaborated. Following this, limitations of the methodology used here, and some
directions for future research, will be discussed. This chapter will end of a brief conclusion for
this dissertation project.
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KEY FINDINGS AND SUGGESTIONS FOR USE IN HEALTH CARE PRACTICE

Medication Non-Adherence Scale
The primary goal of this dissertation was to develop a health care practice setting
administrable, disease non-specific scale for medication non-adherence that can distinguish
between different reasons for non-adherence. Such a scale would not only have the ability to
estimate concurrent medication non-adherence, but also future non-adherence. The results
presented in this document offer evidence for the achievement of these goals. Six and three
month adaptations of the National Committee for Quality Assurance (NCQA) proportion of days
covered (PDC) measure1 were used as criterion measures to concurrently and predictively
validate the MNAS. The NCQA PDC measure is recommended, and used, by certain payers to
enhance reimbursement to health care practitioners. Thus based on the ability of this scale to
estimate PDC, if used in the practice setting, the MNAS may allow practitioners to identify
patients that need medication adherence management, improve their performance measures, and
thus enhance their reimbursement from payers2. A confirmatory factor analysis showed that the
MNAS can be divided into five sub-scales that offer reasons for the non-adherence – intentional
non-adherence due to worries about side-effects, intentional non-adherence due to worries about
addiction, intentional non-adherence due to worries about cost, intentional non-adherence due to
lack of perceived need for the medication, and unintentional non-adherence. The scores obtained
on these sub-scales can be used by health care practitioners to implement appropriate
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interventions to improve their patients’ medication adherence, and thus also reimbursement from
payers.
The MNAS is a sixteen item scale, measured on a five-point scale with options ‘Never’.
‘Rarely’, ‘Sometimes’, ‘Often’, and ‘Always’, scored from 1 through 5. If a patient presents with
a summated score of more than 16 on the scale, the person administering the scale must study the
responses on individual items to identify potential reasons for non-adherence. Such a score may
indicate a PDC of less than 95% in the past 6 months. A summated score of greater than 20 on
the scale may indicate a higher propensity of non-adherence in the next three months (i.e. a PDC
of less than 95%) as well. In order to improve medication adherence, appropriate interventions
should then be implemented based on the patient’s performance on the sub-scales.
Besides demonstrating good psychometric properties, the MNAS was also seen to
perform better than some of the currently used medication adherence and medication adherence
propensity scales. Specifically, this dissertation compared the concurrent PDC estimating ability
of the MNAS with the five-point variant of the 1986 Morisky scale3–6 and the Medication
Adherence Reasons Scale (MAR-Scale)3,4, and its predictive PDC estimating ability against the
Adherence Estimator® (AE)7. Based on our results, the MNAS outperformed all of these scales
in estimating the criterion measures considered.

Medication Non-Persistence Scale
This dissertation also aimed at developing a multi-item self-reported measure for
medication non-persistence. The evidence presented in this document outlines a successful
endeavor. This process was exploratory in nature, as based on our literature review, currently
there are no multi-item instruments that help identify reasons for non-persistence. A series of
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both, qualitative and quantitative, pretest were conducted to arrive at a set of items for this scale.
A confirmatory factor analysis revealed a single factor solution for the Medication NonPersistence Scale (MNPS). In its final version, the MNPS is a nine item scale, designed to obtain
binary ‘yes’ or ‘no’ responses on each item. Each ‘yes’ response receives a score of ‘1’, and each
‘no’ response a score of ‘0’. The MNPS was validated against a standardized patient-specific
mean days to discontinuation measure. The result of a ROC curve analysis concluded that a
summated score greater than zero may indicate non-persistence. If such a score is obtained, the
person administering the scale must inspect the individual items to identify the reason(s) for nonpersistence.
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LIMITATIONS OF THE STUDY AND DIRECTIONS FOR FUTURE RESEARCH

The first limitation of this study is potentially low external validity. The study was
conducted among patrons of three independent community pharmacies in the Southeastern
United States, thus potentially limiting its generalizability to other socio-demographic and
geographic populations. Future research should apply the MNAS and the MNPS in a variety of
settings to test their external validity. This will further strengthen the evidence for reliability,
validity, and applicability of the scales.
The MNAS underwent multiple rounds of qualitative and quantitative pretests. But the
amount of variation explained in the concurrent PDC measure was observed to be low (5.87%).
Based on the results of Pretest 3 in Paper 1, the likelihood of observing this result due to socially
desirable response bias seems unlikely. This may have been observed because of a missing factor
in the scale; medication non-adherence is not only comprised of under-dosing, but also overdosing. Most scales, including the MNAS, only assess under-dosing.* Future research should
address this aspect of non-adherence by adding a factor that measures over-dosing, and identifies
reasons for the same. This may help improve the amount of variation explained in the concurrent
measurement of PDC.
The results of tests for studying concurrent and predictive validity of the MNAS
indicated that current medication-taking behavior may help predict future medication-taking
behavior. This may indicate that medication adherence has certain trait-like aspects. But a lot of
185

the variation in future medication-taking behavior (about 89%) was not explained by the MNAS.
Such a result may indicate presence of state- or occasion-like factors within the construct. Future
research should study the work published by Cole and colleagues in their development of the
Trait-State-Occasion Model8 and the Latent Trait-State-Occasion Model9, and apply it to the
context of medication adherence.
A scale developed for use in the clinical practice setting should ideally be short to
administer. Though the MNAS offers more functionality, better psychometric properties, and
more effective estimation of the PDC than some of the contemporary scale (e.g. 1986 Morisky
scale10, Morisky Medication Adherence Scale11, MAR-Scale3, the Adherence Estimator®7, etc.),
it is longer than most scales currently used in practice. Its length may increase the burden on the
person administering the survey (e.g. pharmacist, pharmacy technician, nurse, etc.). Future
researchers should make an attempt at developing a ‘short-form’ version of the MNAS to reduce
administration times.
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CONCLUSIONS

Despite the strong evidence for detrimental effect of medication non-adherence and nonpersistence12–16, there are quite a few issues with the effective measurement of these constructs in
clinical practice. There are no multi-item instruments to measure medication non-persistence in
clinical practice today. Paper 1 presented evidence for the reliability and validity of such an
instrument – the Medication Non-Persistence Scale (MNPS). Besides estimating days to
discontinuation, and helping identify individuals who may have discontinued their medication in
the past year, the MNPS items also offer reasons for the discontinuation.
There are numerous instruments available to measure medication adherence, but some
instruments do not possess good psychometric properties (e.g. 1986 Morisky scale10), some offer
different factor structures across diseases (e.g. MAR-Scale3), some use different scales for a part
of their items (e.g. RAM scale17), while some require the patients to remember minute details
about the medications that they are taking (Diagnostic Adherence to Medications Scale
(DAMS)18. The Medication Non-Adherence Scale (MNAS) has been designed to be disease nonspecific, and relatively easy to administer in a practice setting. Paper 1 demonstrated evidence
for its internal consistency reliability, convergent, discriminant and concurrent validity, and
ability to distinguish between five reasons for medication non-adherence – worries about sideeffects, worries about addiction to the medication, worries about medication cost, lack of
perceived need for the medication, and unintentional non-adherence. Paper 2 offered evidence
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for its ability to predict future medication non-adherence. Moreover, the MNAS has been
concurrently and predictively validated against adaptations of the National Committee for
Quality Assurance (NCQA) proportion of days covered (PDC) measure1. This measure is used
by the Centers for Medicare and Medicaid Services (CMS), and some private payers, to
determine health care quality and reimbursement.2 Paper 3 concluded that the MNAS was more
effective in estimating concurrent PDC as compared to the 1986 Morisky scale5,6,10 and the
MAR-Scale3, and future PDC as compared to the AE7. Thus, the MNAS is a worthy candidate
for an instrument to identify cases of medication non-adherence, predict its future occurrence,
and distinguish between reasons for non-adherence, in a clinical practice setting.
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